Journal of Movement Disorders

Han-Joon Kim

31 Articles

Evaluating the Validity and Reliability of the Korean Version of the Scales for Outcomes in Parkinson’s Disease–Cognition: Jinse Park, Eungseok Oh, Seong-Beom Koh, In-Uk Song, Tae-Beom Ahn, Sang Jin Kim, Sang-Myung Cheon, Yoon-Joong Kim, Jin Whan Cho, Hyeo-Il Ma, Mee Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, Han-Joon Kim, Young-Hee Sung, Do Young Kwon, Jae-Hyeok Lee, Jee-Young Lee, Ji Seon Kim, Ji Young Yun, Hee Jin Kim, Jin Yong Hong, Mi-Jung Kim, Jinyoung Youn, Hui-Jun Yang, Won Tae Yoon, Sooyeoun You, Kyum-Yil Kwon, Su-Yun Lee, Younsoo Kim, Hee-Tae Kim, Joong-Seok Kim, Ji-Young Kim; J Mov Disord. 2024;17(3):328-332. Published online April 3, 2024; DOI: https://doi.org/10.14802/jmd.24061

1,332 View
70 Download

Abstract PDF Supplementary Material: Objective
The Scales for Outcomes in Parkinson’s Disease–Cognition (SCOPA-Cog) was developed to assess cognition in patients with Parkinson’s disease (PD). In this study, we aimed to evaluate the validity and reliability of the Korean version of the SCOPACog (K-SCOPA-Cog).
Methods
We enrolled 129 PD patients with movement disorders from 31 clinics in South Korea. The original version of the SCOPA-Cog was translated into Korean using the translation-retranslation method. The test–retest method with an intraclass correlation coefficient (ICC) and Cronbach’s alpha coefficient were used to assess reliability. Spearman’s rank correlation analysis with the Montreal Cognitive Assessment-Korean version (MOCA-K) and the Korean Mini-Mental State Examination (K-MMSE) were used to assess concurrent validity.
Results
The Cronbach’s alpha coefficient was 0.797, and the ICC was 0.887. Spearman’s rank correlation analysis revealed a significant correlation with the K-MMSE and MOCA-K scores (r = 0.546 and r = 0.683, respectively).
Conclusion
Our results demonstrate that the K-SCOPA-Cog has good reliability and validity.

A Survey of Perspectives on Telemedicine for Patients With Parkinson’s Disease: Jae Young Joo, Ji Young Yun, Young Eun Kim, Yu Jin Jung, Ryul Kim, Hui-Jun Yang, Woong-Woo Lee, Aryun Kim, Han-Joon Kim; J Mov Disord. 2024;17(1):89-93. Published online August 22, 2023; DOI: https://doi.org/10.14802/jmd.23130

2,092 View
314 Download

Abstract PDF Supplementary Material: Objective
Parkinson’s disease (PD) patients often find it difficult to visit hospitals because of motor symptoms, distance to the hospital, or the absence of caregivers. Telemedicine is one way to solve this problem.
Methods
We surveyed 554 PD patients from eight university hospitals in Korea. The questionnaire consisted of the clinical characteristics of the participants, possible teleconferencing methods, and preferences for telemedicine.
Results
A total of 385 patients (70%) expressed interest in receiving telemedicine. Among them, 174 preferred telemedicine whereas 211 preferred in-person visits. The longer the duration of disease, and the longer the time required to visit the hospital, the more patients were interested in receiving telemedicine.
Conclusion
This is the first study on PD patients’ preferences regarding telemedicine in Korea. Although the majority of patients with PD have a positive view of telemedicine, their interest in receiving telemedicine depends on their different circumstances.

Caregiver Burden of Patients With Huntington’s Disease in South Korea: Chan Young Lee, Chaewon Shin, Yun Su Hwang, Eungseok Oh, Manho Kim, Hyun Sook Kim, Sun Ju Chung, Young Hee Sung, Won Tae Yoon, Jin Whan Cho, Jae-Hyeok Lee, Han-Joon Kim, Hee Jin Chang, Beomseok Jeon, Kyung Ah Woo, Seong-Beom Koh, Kyum-Yil Kwon, Jangsup Moon, Young Eun Kim, Jee-Young Lee; J Mov Disord. 2024;17(1):30-37. Published online September 11, 2023; DOI: https://doi.org/10.14802/jmd.23134

3,575 View
338 Download
1 Web of Science
1 Crossref
1 Comments

Abstract PDF Supplementary Material

Objective
This is the first prospective cohort study of Huntington’s disease (HD) in Korea. This study aimed to investigate the caregiver burden in relation to the characteristics of patients and caregivers.
Methods
From August 2020 to February 2022, we enrolled patients with HD from 13 university hospitals in Korea. We used the 12-item Zarit Burden Interview (ZBI-12) to evaluate the caregiver burden. We evaluated the clinical associations of the ZBI-12 scores by linear regression analysis and investigated the differences between the low- and high-burden groups.
Results
Sixty-five patients with HD and 45 caregivers were enrolled in this cohort study. The average age at onset of motor symptoms was 49.3 ± 12.3 years, with an average cytosine-adenine-guanine (CAG)n of 42.9 ± 4.0 (38–65). The median ZBI-12 score among our caregivers was 17.6 ± 14.2. A higher caregiver burden was associated with a more severe Shoulson–Fahn stage (p = 0.038) of the patients. A higher ZBI-12 score was also associated with lower independence scale (B = -0.154, p = 0.006) and functional capacity (B = -1.082, p = 0.002) scores of patients. The caregiving duration was longer in the high- than in the low-burden group. Caregivers’ demographics, blood relation, and marital and social status did not affect the burden significantly.
Conclusion
HD patients’ neurological status exerts an enormous impact on the caregiver burden regardless of the demographic or social status of the caregiver. This study emphasizes the need to establish an optimal support system for families dealing with HD in Korea. A future longitudinal analysis could help us understand how disease progression aggravates the caregiver burden throughout the entire disease course.

Citations

Citations to this article as recorded by

A Practical Guide for Clinical Approach to Patients With Huntington’s Disease in Korea
Chaewon Shin, Ryul Kim, Dallah Yoo, Eungseok Oh, Jangsup Moon, Minkyeong Kim, Jee-Young Lee, Jong-Min Kim, Seong-Beom Koh, Manho Kim, Beomseok Jeon
Journal of Movement Disorders.2024; 17(2): 138. CrossRef

Absence of Alpha-Synuclein Pathology in the Stomach of a Patient With Prodromal Dementia With Lewy Bodies: Chaewon Shin, Seong-Ik Kim, Sung-Hye Park, Jung Hwan Shin, Chan Young Lee, Han-Joon Kim, Hyuk-Joon Lee, Seong-Ho Kong, Yun-Suhk Suh, Han-Kwang Yang, Beomseok Jeon; J Mov Disord. 2023;16(2):213-216. Published online April 26, 2023; DOI: https://doi.org/10.14802/jmd.22219

1,318 View
66 Download

PDF Supplementary Material

Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease: Sangmin Park, Jung Hwan Shin, Seung Ho Jeon, Chan Young Lee, Han-Joon Kim, Beomseok Jeon; J Mov Disord. 2023;16(2):224-226. Published online May 24, 2023; DOI: https://doi.org/10.14802/jmd.23037

1,887 View
72 Download

PDF Supplementary Material

Challenges in Parkinson’s Disease Care—In Light of the COVID-19 Pandemic: Kyung Ah Woo, Han-Joon Kim, Beomseok Jeon; J Mov Disord. 2023;16(1):52-54. Published online November 10, 2022; DOI: https://doi.org/10.14802/jmd.22085

2,717 View
87 Download
1 Web of Science
1 Crossref

PDF

Citations

Citations to this article as recorded by

Efficacy of telerehabilitation with digital and robotic tools for the continuity of care of people with chronic neurological disorders: The TELENEURO@REHAB protocol for a randomized controlled trial
Federica Rossetto, Fabiola Giovanna Mestanza Mattos, Elisa Gervasoni, Marco Germanotta, Arianna Pavan, Davide Cattaneo, Irene Aprile, Francesca Baglio
DIGITAL HEALTH.2024;[Epub] CrossRef

First Cases of Spinocerebellar Ataxia 42 in Two Korean Families: Hyoshin Son, Jihoon G. Yoon, Man Jin Kim, Jangsup Moon, Han-Joon Kim; J Mov Disord. 2023;16(1):110-113. Published online January 12, 2023; DOI: https://doi.org/10.14802/jmd.22150

1,887 View
53 Download
1 Web of Science
1 Crossref

PDF Supplementary Material

Citations

Citations to this article as recorded by

Targeting Ion Channels and Purkinje Neuron Intrinsic Membrane Excitability as a Therapeutic Strategy for Cerebellar Ataxia
Haoran Huang, Vikram G. Shakkottai
Life.2023; 13(6): 1350. CrossRef

Semiautomated Algorithm for the Diagnosis of Multiple System Atrophy With Predominant Parkinsonism: Woong-Woo Lee, Han-Joon Kim, Hong Ji Lee, Han Byul Kim, Kwang Suk Park, Chul-Ho Sohn, Beomseok Jeon; J Mov Disord. 2022;15(3):232-240. Published online July 26, 2022; DOI: https://doi.org/10.14802/jmd.21178

2,914 View
123 Download
2 Web of Science
1 Crossref

Abstract PDF Supplementary Material

Objective
Putaminal iron deposition is an important feature that helps differentiate multiple system atrophy with predominant parkinsonism (MSA-p) from Parkinson’s disease (PD). Most previous studies used visual inspection or quantitative methods with manual manipulation to perform this differentiation. We investigated the value of a new semiautomated diagnostic algorithm using 3T-MR susceptibility-weighted imaging for MSA-p.
Methods
This study included 26 MSA-p, 68 PD, and 41 normal control (NC) subjects. The algorithm was developed in 2 steps: 1) determine the image containing the remarkable putaminal margin and 2) calculate the phase-shift values, which reflect the iron concentration. The next step was to identify the best differentiating conditions among several combinations. The highest phaseshift value of each subject was used to assess the most effective diagnostic set.
Results
The raw phase-shift values were present along the lateral margin of the putamen in each group. It demonstrates an anterior- to-posterior gradient that was identified most frequently in MSA-p. The average of anterior 5 phase shift values were used for normalization. The highest area under the receiver operating characteristic curve (0.874, 80.8% sensitivity, and 86.7% specificity) of MSA-p versus PD was obtained under the combination of 3 or 4 vertical pixels and one dominant side when the normalization methods were applied. In the subanalysis for the MSA-p patients with a longer disease duration, the performance of the algorithm improved.
Conclusion
This algorithm detected the putaminal lateral margin well, provided insight into the iron distribution of the putaminal rim of MSA-p, and demonstrated good performance in differentiating MSA-p from PD.

Citations

Citations to this article as recorded by

Ocular vestibular-evoked myogenic potential assists in differentiation of multiple system atrophy from Parkinson’s disease
Keun-Tae Kim, Kyoungwon Baik, Sun-Uk Lee, Euyhyun Park, Chan-Nyoung Lee, Donghoon Woo, Yukang Kim, Seoui Kwag, Hyunsoh Park, Ji-Soo Kim
Journal of Movement Disorders.2024;[Epub] CrossRef

Long-Term Outcomes of Deep Brain Stimulation in Pantothenate Kinase-Associated Neurodegeneration-Related Dystonia: Kyung Ah Woo, Han-Joon Kim, Seung-Ho Jeon, Hye Ran Park, Kye Won Park, Seung Hyun Lee, Sun Ju Chung, Jong-Hee Chae, Sun Ha Paek, Beomseok Jeon; J Mov Disord. 2022;15(3):241-248. Published online July 26, 2022; DOI: https://doi.org/10.14802/jmd.22002

3,556 View
185 Download
3 Web of Science
4 Crossref

Abstract PDF Supplementary Material

Objective
To investigate the long-term clinical outcomes of pallidal deep brain stimulation (GPi-DBS) in patients with pantothenate kinase-associated neurodegeneration (PKAN).
Methods
We reviewed the records of patients with genetically confirmed PKAN who received bilateral GPi-DBS for refractory dystonia and were clinically followed up for at least 2 years postoperatively at two centers in Korea. Pre- and postoperative Burke– Fahn–Marsden Dystonia Rating Scale motor subscale (BFMDRS-M) scores, disability subscale (BFMDRS-D) scores, and qualitative clinical information were prospectively collected. Descriptive analysis was performed for BFMDRS-M scores, BFMDRSD scores, and the orofacial, axial, and limb subscores of the BFMDRS-M at 6–12, 24–36, and 60–72 months postoperatively.
Results
Five classic-type, four atypical-type, and one unknown-type PKAN cases were identified. The mean preoperative BFMDRS-M score was 92.1 for the classic type and 38.5 for the atypical or unknown type, with a mean BFMDRS follow-up of 50.7 months and a clinical follow-up of 69.0 months. The mean improvements in BFMDRS-M score were 11.3%, 41.3%, and 30.5% at 6–12, 24–36, and 60–72 months, respectively. In four patients with full regular evaluations until 60–72 months, improvements in the orofacial, axial, and limb subscores persisted, but the disability scores worsened from 24–36 months post-operation compared to the baseline, mainly owing to the aggravation of eating and feeding disabilities.
Conclusion
The benefits of GPi-DBS on dystonia may persist for more than 5 years in PKAN. The effects on patients’ subjective disability may have a shorter duration despite improvements in dystonia owing to the complex manifestations of PKAN.

Citations

Citations to this article as recorded by

Deep Brain Stimulation for Refractory Status Dystonicus in Children: Multicenter Case Series and Systematic Review
Lindsey M. Vogt, Han Yan, Brendan Santyr, Sara Breitbart, Melanie Anderson, Jürgen Germann, Karlo J. Lizarraga, Angela L. Hewitt, Alfonso Fasano, George M. Ibrahim, Carolina Gorodetsky
Annals of Neurology.2024; 95(1): 156. CrossRef
Illustration of the long-term efficacy of pallidal deep brain stimulation in a patient with PKAN dystonia
Luigi M. Romito, Fabiana Colucci, Giovanna Zorzi, Barbara Garavaglia, Ahmet Kaymak, Alberto Mazzoni, Celeste Panteghini, Nico Golfrè Andreasi, Sara Rinaldo, Vincenzo Levi, Miryam Carecchio, Roberto Eleopra
Parkinsonism & Related Disorders.2024; 123: 106977. CrossRef
Case of Hallervorden–Spatz Syndrome: A Tale of Twin Sisters
Naveen Reddy, Jitender Sharma, Anmol Sharma
Neurology India.2024; 72(2): 411. CrossRef
Surgical treatment of movement disorders in neurometabolic conditions
Alonso Zea Vera, Andrea L. Gropman
Frontiers in Neurology.2023;[Epub] CrossRef

Sensitivity of Detecting Alpha-Synuclein Accumulation in the Gastrointestinal Tract and Tissue Volume Examined: Chaewon Shin, Seong-Ik Kim, Sung-Hye Park, Jung Hwan Shin, Chan Young Lee, Han-Kwang Yang, Hyuk-Joon Lee, Seong-Ho Kong, Yun-Suhk Suh, Han-Joon Kim, Beomseok Jeon; J Mov Disord. 2022;15(3):264-268. Published online July 26, 2022; DOI: https://doi.org/10.14802/jmd.22042

3,301 View
112 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material

Objective
This study aimed to evaluate whether a larger tissue volume increases the sensitivity of detecting alpha-synuclein (AS) pathology in the gastrointestinal (GI) tract.
Methods
Nine patients with Parkinson’s disease (PD) or idiopathic rapid eye movement sleep disorder (iRBD) who underwent GI operation and had full-depth intestinal blocks were included. All patients were selected from our previous study population. A total of 10 slides (5 serial sections from the proximal and distal blocks) per patient were analyzed.
Results
In previous studies, pathologic evaluation revealed phosphorylated AS (+) in 5/9 patients (55.6%) and in 1/5 controls (20.0%); in this extensive examination, this increased to 8/9 patients (88.9%) but remained the same in controls (20.0%). The severity and distribution of positive findings were similar between patients with iRBD and PD.
Conclusion
Examining a large tissue volume increased the sensitivity of detecting AS accumulation in the GI tract.

Citations

Citations to this article as recorded by

Symmetric and Profound Monoaminergic Degeneration in Parkinson’s Disease with Premotor REM Sleep Behavior Disorder
Kyung Ah Woo, Han-Joon Kim, Jung Hwan Shin, Kangyoung Cho, Hongyoon Choi, Beomseok Jeon
Journal of Parkinson's Disease.2024; 14(4): 823. CrossRef

A Case of AOA2 With Compound Heterozygous SETX Mutations: Hee Jin Chang, Ryul Kim, Minchae Kim, Jangsup Moon, Man Jin Kim, Han-Joon Kim; J Mov Disord. 2022;15(2):178-180. Published online December 24, 2021; DOI: https://doi.org/10.14802/jmd.21139

3,115 View
242 Download

PDF

Automatic Measurement of Postural Abnormalities With a Pose Estimation Algorithm in Parkinson’s Disease: Jung Hwan Shin, Kyung Ah Woo, Chan Young Lee, Seung Ho Jeon, Han-Joon Kim, Beomseok Jeon; J Mov Disord. 2022;15(2):140-145. Published online January 19, 2022; DOI: https://doi.org/10.14802/jmd.21129

3,668 View
271 Download
4 Web of Science
5 Crossref

Abstract PDF Supplementary Material

Objective
This study aims to develop an automated and objective tool to evaluate postural abnormalities in Parkinson’s disease (PD) patients.
Methods
We applied a deep learning-based pose-estimation algorithm to lateral photos of prospectively enrolled PD patients (n = 28). We automatically measured the anterior flexion angle (AFA) and dropped head angle (DHA), which were validated with conventional manual labeling methods.
Results
The automatically measured DHA and AFA were in excellent agreement with manual labeling methods (intraclass correlation coefficient > 0.95) with mean bias equal to or less than 3 degrees.
Conclusion
The deep learning-based pose-estimation algorithm objectively measured postural abnormalities in PD patients.

Citations

Citations to this article as recorded by

Botulinum Toxin for Axial Postural Abnormalities in Parkinson’s Disease: A Systematic Review
Marialuisa Gandolfi, Carlo Alberto Artusi, Gabriele Imbalzano, Serena Camozzi, Mauro Crestani, Leonardo Lopiano, Michele Tinazzi, Christian Geroin
Toxins.2024; 16(5): 228. CrossRef
Research Progress of Camptocormia in Parkinson Disease
Yilin Lu, Xiang Zhang, Junyu Li, Weishi Li, Miao Yu
Clinical Spine Surgery.2024;[Epub] CrossRef
Three‐Dimensional Mesh Recovery from Common 2‐Dimensional Pictures for Automated Assessment of Body Posture in Camptocormia
Robin Wolke, Olga Gavriliuc, Oliver Granert, Günther Deuschl, Nils G. Margraf
Movement Disorders Clinical Practice.2023; 10(3): 472. CrossRef
Assessment of Axial Postural Abnormalities in Parkinsonism: Automatic Picture Analysis Software
Carlo Alberto Artusi, Christian Geroin, Gabriele Imbalzano, Serena Camozzi, Stefano Aldegheri, Leonardo Lopiano, Michele Tinazzi, Nicola Bombieri
Movement Disorders Clinical Practice.2023; 10(4): 636. CrossRef
Camera- and Viewpoint-Agnostic Evaluation of Axial Postural Abnormalities in People with Parkinson’s Disease through Augmented Human Pose Estimation
Stefano Aldegheri, Carlo Alberto Artusi, Serena Camozzi, Roberto Di Marco, Christian Geroin, Gabriele Imbalzano, Leonardo Lopiano, Michele Tinazzi, Nicola Bombieri
Sensors.2023; 23(6): 3193. CrossRef

Development of Clinical Milestones in Parkinson’s Disease After Bilateral Subthalamic Deep Brain Stimulation: Jed Noel A. Ong, Jung Hwan Shin, Seungho Jeon, Chan Young Lee, Han-Joon Kim, Sun Ha Paek, Beomseok Jeon; J Mov Disord. 2022;15(2):124-131. Published online May 26, 2022; DOI: https://doi.org/10.14802/jmd.21106

3,001 View
148 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material

Objective
Deep brain stimulation of the subthalamic nucleus (STN-DBS) in Parkinson’s disease (PD) patients does not halt disease progression, as these patients will progress and develop disabling non-levodopa responsive symptoms. These features may act as milestones that represent the overall functionality of patients after DBS. The objective of this study was to investigate the development of clinical milestones in advanced PD patients who underwent bilateral STN-DBS.
Methods
The study evaluated PD patients who underwent STN-DBS at baseline up to their last follow-up using the Unified Parkinson’s Disease Rating Scale and Hoehn and Yahr scale. The symptoms of hallucinations, dysarthria, dysphagia, frequent falls, difficulty walking, cognitive impairment and the loss of autonomy were chosen as the clinical milestones.
Results
A total of 106 patients with a mean age of 47.21 ± 10.52 years at disease onset, a mean age of 58.72 ± 8.74 years at surgery and a mean disease duration of 11.51 ± 4.4 years before surgery were included. Initial improvement of motor symptoms was seen after the surgery with the appearance of clinical milestones over time. Using the moderately disabling criteria, 81 patients (76.41%) developed at least one clinical milestone, while 48 patients (45.28%) developed a milestone when using the severely disabling criteria.
Conclusion
STN-DBS has a limited effect on axial and nonmotor symptoms of the PD patients, in contrast to the effect on motor symptoms. These symptoms may serve as clinical milestones that can convey the status of PD patients and its impact on the patients and their caregivers. Therefore, advanced PD patients, even those treated with bilateral STN-DBS, will still require assistance and cannot live independently in the long run.

Citations

Citations to this article as recorded by

Unveiling the Impact of Outpatient Physiotherapy on Specific Motor Symptoms in Parkinson’s Disease: A Prospective Cohort Study
Yuta Terasawa, Koki Ikuno, Shintaro Fujii, Yuki Nishi, Emi Tanizawa, Sachio Nabeshima, Yohei Okada
Brain & Neurorehabilitation.2023;[Epub] CrossRef

Investigation of Nocturnal Hypokinesia and Health-Related Quality of Life in Parkinsonian Patients with the Korean Version of the Nocturnal Hypokinesia Questionnaire: Ji-Hyun Choi, Jee-Young Lee, Chaewon Shin, Dallah Yoo, Jin Hee Im, Kyung Ah Woo, Han-Joon Kim, Tae-Beom Ahn, Jong-Min Kim, Beomseok Jeon; J Mov Disord. 2021;14(3):221-225. Published online May 26, 2021; DOI: https://doi.org/10.14802/jmd.20172

4,812 View
75 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material

Objective
To assess nocturnal hypokinesia using the Korean version of the Nocturnal Hypokinesia Questionnaire (NHQ-K) in Parkinson’s disease (PD) patients across disease stages.
Methods
We developed the NHQ-K and performed questionnaire-based interviews with 108 PD patients from three referral hospitals. Clinical associations of nocturnal hypokinesia and its impact on health-related quality of life (HRQoL) were also analyzed.
Results
The NHQ-K showed acceptable internal consistency (0.83) and interrater reliability (0.95). Nocturnal hypokinesia significantly affected HRQoL in PD patients at both the early and advanced stages (adjusted p < 0.001). Increased severity of nocturnal hypokinesia was associated with dyskinesias, off-period disability, apathy, and anxious mood in PD patients (adjusted p < 0.01) after controlling for disease severity and medication dose.
Conclusion
The NHQ-K is useful for screening nocturnal hypokinesia in PD patients. Given the high impact of nocturnal hypokinesia on HRQoL, comprehensive management of nocturnal disability is needed for PD patients.

Citations

Citations to this article as recorded by

Technological evaluation of strategies to get out of bed by people with Parkinson's disease: Insights from multisite wearable sensors
Jirada Sringean, Chusak Thanawattano, Roongroj Bhidayasiri
Frontiers in Medical Technology.2022;[Epub] CrossRef

Young-Onset Parkinson’s Disease with Impulse Control Disorder Due to Novel Variants of F-Box Only Protein 7: Dallah Yoo, Ji-Hyun Choi, Jin-Hee Im, Man Jin Kim, Han-Joon Kim, Sung Sup Park, Beomseok Jeon; J Mov Disord. 2020;13(3):225-228. Published online September 9, 2020; DOI: https://doi.org/10.14802/jmd.20026

5,601 View
119 Download
4 Web of Science
4 Crossref

Abstract PDF

F-box only protein 7 (FBXO7) is a rare monogenic cause of hereditary Parkinson’s disease (PD) with an autosomal recessive mode of inheritance and a broad spectrum of clinical manifestations. Here, we report a de novo PD patient with onset at the age of 28 with novel compound heterozygous variants in the FBXO7 gene (c.1162C>T, p.Gln388X; c.80G>A, p.Arg27His). The clinical features of the patient were problematic impulse control disorder behaviors and pyromania, and pyramidal signs were negative. We describe the novel pathogenic variants of the FBXO7 gene with detailed clinical pictures to report the expanding genotypes and phenotypes of FBXO7-associated parkinsonism.

Citations

Citations to this article as recorded by

Global prevalence and incidence of Young Onset Parkinson’s disease: A systematic review and meta-analysis
Fardin Nabizadeh, Homa Seyedmirzaei, Nazanin Rafiei, Seyedeh Maryam Vafaei, Dorsa Shekouh, Ehsan Mehrtabar, Ehsan Mirzaaghazadeh, Zahra Mirzaasgari
Journal of Clinical Neuroscience.2024; 125: 59. CrossRef
Study of an FBXO7 patient mutation reveals Fbxo7 and PI31 co‐regulate proteasomes and mitochondria
Sara Al Rawi, Lorna Simpson, Guðrún Agnarsdóttir, Neil Q. McDonald, Veronika Chernuha, Orly Elpeleg, Massimo Zeviani, Roger A. Barker, Ronen Spiegel, Heike Laman
The FEBS Journal.2024; 291(12): 2565. CrossRef
Loss of the parkinsonism‐associated protein FBXO7 in glutamatergic forebrain neurons in mice leads to abnormal motor behavior and synaptic defects
Jingbo Wang, Sabitha Joseph, Siv Vingill, Ekrem Dere, Lars Tatenhorst, Anja Ronnenberg, Paul Lingor, Christian Preisinger, Hannelore Ehrenreich, Jörg B. Schulz, Judith Stegmüller
Journal of Neurochemistry.2023; 167(2): 296. CrossRef
Nearly Abolished Dopamine Transporter Uptake in a Patient With a Novel FBXO7 Mutation
Eun Young Kim, Seon Young Kim, Youngduk Seo, Chaewon Shin
Journal of Movement Disorders.2022; 15(3): 269. CrossRef

A Rare Case of Late Adult-Onset Niemann-Pick Disease Type C: Ryul Kim, Dallah Yoo, Sangmin Park, Jung Hwan Shin, Ji-Hyun Choi, Han-Joon Kim, Beomseok Jeon; J Mov Disord. 2020;13(2):163-165. Published online March 18, 2020; DOI: https://doi.org/10.14802/jmd.19077

7,547 View
218 Download
3 Web of Science
3 Crossref

PDF Supplementary Material

Citations

Citations to this article as recorded by

Lysosomal storage disorders identified in adult population from India: Experience of a tertiary genetic centre and review of literature
Jayesh Sheth, Aadhira Nair, Riddhi Bhavsar, Koumudi Godbole, Chaitanya Datar, Sheela Nampoothiri, Inusha Panigrahi, Heli Shah, Shruti Bajaj, Naresh Tayade, Naveen Bhardwaj, Harsh Sheth
JIMD Reports.2024; 65(2): 85. CrossRef
Genetic and phenotypic variability in adult patients with Niemann Pick type C from Serbia: single-center experience
Nikola Kresojević, Valerija Dobričić, Milica Ječmenica Lukić, Aleksandra Tomić, Igor Petrović, Nataša Dragašević, Ivana Perović, Ana Marjanović, Marija Branković, Milena Janković, Ivana Novaković, Marina Svetel, Vladimir S. Kostić
Journal of Neurology.2022; 269(6): 3167. CrossRef
Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life
Melanie Wu, Rita Ceponiene, Ece Bayram, Irene Litvan
Movement Disorders Clinical Practice.2020; 7(8): 961. CrossRef

Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies: Junghwan Shin, Han-Joon Kim, Beomseok Jeon; J Mov Disord. 2020;13(1):11-19. Published online December 19, 2019; DOI: https://doi.org/10.14802/jmd.19057

11,804 View
481 Download
20 Web of Science
20 Crossref

Abstract PDF

α-Synuclein and tau deposition in the central nervous system is responsible for various parkinsonian syndromes, including Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. Emerging evidence has suggested that pathologic α-synuclein and tau are transmitted from cell to cell and further accelerate the aggregation of pathologic proteins in neighboring cells. Furthermore, extracellular pathologic proteins have also been reported to provoke inflammatory responses that lead to neurodegeneration. Therefore, immunotherapies targeting extracellular α-synuclein and tau have been proposed as potential disease-modifying strategies. In this review, we summarize completed phase I trials and ongoing phase II trials of immunotherapies against α-synuclein and tau and further discuss concerns and hurdles to overcome in the future.

Citations

Citations to this article as recorded by

Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration
Wen Li, Jia-Yi Li
Translational Neurodegeneration.2024;[Epub] CrossRef
Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance
Dnyandev G. Gadhave, Vrashabh V. Sugandhi, Saurav Kumar Jha, Sopan N. Nangare, Gaurav Gupta, Sachin Kumar Singh, Kamal Dua, Hyunah Cho, Philip M. Hansbro, Keshav Raj Paudel
Ageing Research Reviews.2024; 99: 102357. CrossRef
Modeling the dynamics of innate and adaptive immune response to Parkinson's disease with immunotherapy
Salma M. Al-Tuwairqi, Asma A. Badrah
AIMS Mathematics.2023; 8(1): 1800. CrossRef
Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy
Winston T. Chu, Jesse Hall, Anjela Gurrala, Alexander Becsey, Shreya Raman, Michael S. Okun, Catherine T. Flores, Benoit I. Giasson, David E. Vaillancourt, Vinata Vedam-Mai
ACS Chemical Neuroscience.2023; 14(2): 235. CrossRef
Direct digital sensing of protein biomarkers in solution
Georg Krainer, Kadi L. Saar, William E. Arter, Timothy J. Welsh, Magdalena A. Czekalska, Raphaël P. B. Jacquat, Quentin Peter, Walther C. Traberg, Arvind Pujari, Akhila K. Jayaram, Pavankumar Challa, Christopher G. Taylor, Lize-Mari van der Linden, Titus
Nature Communications.2023;[Epub] CrossRef
Inflammation in multiple system atrophy
Marta Leńska-Mieciek, Natalia Madetko-Alster, Piotr Alster, Leszek Królicki, Urszula Fiszer, Dariusz Koziorowski
Frontiers in Immunology.2023;[Epub] CrossRef
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare
Acta Neuropathologica.2022; 143(1): 55. CrossRef
Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies
Changyoun Kim, Armine Hovakimyan, Karen Zagorski, Tatevik Antonyan, Irina Petrushina, Hayk Davtyan, Gor Chailyan, Jonathan Hasselmann, Michiyo Iba, Anthony Adame, Edward Rockenstein, Marcell Szabo, Mathew Blurton-Jones, David H. Cribbs, Anahit Ghochikyan,
npj Vaccines.2022;[Epub] CrossRef
Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy
Thuy Thi Lai, Yun Joong Kim, Hyeo-il Ma, Young Eun Kim
Journal of Movement Disorders.2022; 15(1): 1. CrossRef
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies
Dhanya Vijayakumar, Joseph Jankovic
CNS Drugs.2022; 36(4): 327. CrossRef
Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases
Urmi Sengupta, Rakez Kayed
Progress in Neurobiology.2022; 214: 102270. CrossRef
Modeling the dynamics of innate immune response to Parkinson disease with therapeutic approach
Asma Badrah, Salma Al-Tuwairqi
Physical Biology.2022; 19(5): 056004. CrossRef
Potential of food-derived bioactive peptides in alleviation and prevention of Alzheimer's disease
Le Zhao, Dan Li, Xiaofen Qi, Kaifang Guan, Haoran Chen, Rongchun Wang, Ying Ma
Food & Function.2022; 13(21): 10851. CrossRef
Harnessing the immune system for the treatment of Parkinson’s disease
Vinata Vedam-Mai
Brain Research.2021; 1758: 147308. CrossRef
The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease
Katja Badanjak, Sonja Fixemer, Semra Smajić, Alexander Skupin, Anne Grünewald
International Journal of Molecular Sciences.2021; 22(9): 4676. CrossRef
Viral alpha-synuclein knockdown prevents spreading synucleinopathy
Sindhu Menon, Rikke H Kofoed, Fadl Nabbouh, Kristiana Xhima, Yasmeen Al-Fahoum, Tammy Langman, Howard T J Mount, Lamya S Shihabuddin, S Pablo Sardi, Paul E Fraser, Joel C Watts, Isabelle Aubert, Anurag Tandon
Brain Communications.2021;[Epub] CrossRef
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Somin Kwon, Michiyo Iba, Changyoun Kim, Eliezer Masliah
Neurotherapeutics.2020; 17(3): 935. CrossRef
The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease
Kyu-Young Sim, Kyeong Chan Im, Sung-Gyoo Park
International Journal of Molecular Sciences.2020; 21(15): 5295. CrossRef
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll
Alzheimer's Research & Therapy.2020;[Epub] CrossRef
New Insights Into Drug Discovery Targeting Tau Protein
Yoshiyuki Soeda, Akihiko Takashima
Frontiers in Molecular Neuroscience.2020;[Epub] CrossRef

Successful Pallidal Deep Brain Stimulation in a Patient with Childhood-Onset Generalized Dystonia with ANO3 Mutation: Dallah Yoo, Han-Joon Kim, Jong-Hee Chae, Sun Ha Paek, Beomseok Jeon; J Mov Disord. 2019;12(3):190-191. Published online July 17, 2019; DOI: https://doi.org/10.14802/jmd.19016

5,741 View
126 Download
9 Web of Science
9 Crossref

PDF Supplementary Material

Citations

Citations to this article as recorded by

The Clinical Spectrum of ANO3—Report of a New Family and Literature Review
Marco Percetti, Michela Zini, Paola Soliveri, Filippo Cogiamanian, Mariarosa Ferrara, Eva Orunesu, Alessandra Ranghetti, Carlo Ferrarese, Gianni Pezzoli, Barbara Garavaglia, Ioannis Ugo Isaias, Giorgio Sacilotto
Movement Disorders Clinical Practice.2024; 11(3): 289. CrossRef
The role of genetics in the treatment of dystonia with deep brain stimulation: Systematic review and Meta-analysis
Harini Sarva, Federico Rodriguez-Porcel, Francisco Rivera, Claudio Daniel Gonzalez, Samantha Barkan, Susmit Tripathi, Emilia Gatto, Pedro Garcia Ruiz
Journal of the Neurological Sciences.2024; 459: 122970. CrossRef
A novel ANO3 variant in two siblings with different phenotypes
Marcello Esposito, Assunta Trinchillo, Francesca Piceci-Sparascio, Maria Cecilia D'Asdia, Federica Consoli, Alessandro De Luca
Parkinsonism & Related Disorders.2023; 111: 105413. CrossRef
DBS-Evoked Pallidal Activity Correlates with Clinical Improvement in a Patient with ANO3-Related Dystonia
Aditya Boddu, Adam Bashir, Mohammad Awad, Barton Guthrie, Harrison Walker
SSRN Electronic Journal.2023;[Epub] CrossRef
Deep Brain Stimulation in Dystonia: Disentangling Heterogeneity
Alberto Albanese
Movement Disorders Clinical Practice.2021; 8(1): 6. CrossRef
Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome
Stephen Tisch, Kishore Raj Kumar
Frontiers in Neurology.2021;[Epub] CrossRef
The expanding clinical and genetic spectrum of ANO3 dystonia
Li-Ting Jiang, Li-Xi Li, Ying Liu, Xiao-Long Zhang, You-Gui Pan, Lin Wang, Xin-Hua Wan, Ling-Jing Jin
Neuroscience Letters.2021; 746: 135590. CrossRef
Huntington disease-like phenotype in a patient with ANO3 mutation
Shahedah Koya Kutty, Eoin Mulroy, Francesca Magrinelli, Giulia Di Lazzaro, Anna Latorre, Kailash P. Bhatia
Parkinsonism & Related Disorders.2021; 90: 120. CrossRef
Arching deep brain stimulation in dystonia types
Han-Joon Kim, Beomseok Jeon
Journal of Neural Transmission.2021; 128(4): 539. CrossRef

Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment: Jee-Young Lee, Eun Jin Yoon, Yu Kyeong Kim, Chae Won Shin, Hyunwoo Nam, Jae Min Jeong, Han-Joon Kim, Beomseok Jeon; J Mov Disord. 2019;12(2):103-112. Published online May 30, 2019; DOI: https://doi.org/10.14802/jmd.18061

7,853 View
210 Download
19 Web of Science
17 Crossref

Abstract PDF Supplementary Material

Objective
It is unclear whether the decline in dopamine transporters (DAT) differs among idiopathic rapid eye movement sleep behavior disorder (iRBD) patients with different levels of olfactory impairment. This study aimed to characterize DAT changes in relation to nonmotor features in iRBD patients by olfactory loss.
Methods
This prospective cohort study consisted of three age-matched groups: 30 polysomnography-confirmed iRBD patients, 30 drug-naïve Parkinson’s disease patients, and 19 healthy controls without olfactory impairment. The iRBD group was divided into two groups based on olfactory testing results. Participants were evaluated for reported prodromal markers and then underwent 18F-FP-CIT positron emission tomography and 3T MRI. Tracer uptakes were analyzed in the caudate, anterior and posterior putamen, substantia nigra, and raphe nuclei.
Results
Olfactory impairment was defined in 38.5% of iRBD patients. Mild parkinsonian signs and cognitive functions were not different between the two iRBD subgroups; however, additional prodromal features, constipation, and urinary and sexual dysfunctions were found in iRBD patients with olfactory impairment but not in those without. Tracer uptake showed significant group differences in all brain regions, except the raphe nuclei. The iRBD patients with olfactory impairment had uptake reductions in the anterior and posterior putamen, caudate, and substantia nigra (p < 0.016 in all, adjusted for age), which ranged from 0.6 to 0.8 of age-normative values. In contrast, those without olfactory impairment had insignificant changes in all regions ranging above 0.8.
Conclusion
There was a clear distinction in DAT loss and nonmotor profiles by olfactory status in iRBD.

Citations

Citations to this article as recorded by

Neuropsychological Changes in Isolated REM Sleep Behavior Disorder: A Systematic Review and Meta-analysis of Cross-sectional and Longitudinal Studies
Caterina Leitner, Giada D’Este, Laura Verga, Shady Rahayel, Samantha Mombelli, Marco Sforza, Francesca Casoni, Marco Zucconi, Luigi Ferini-Strambi, Andrea Galbiati
Neuropsychology Review.2024; 34(1): 41. CrossRef
Dopamine transporter positron emission tomography in patients with Alzheimer’s disease with Lewy body disease features
Sungwoo Kang, Seun Jeon, Young-gun Lee, Byoung Seok Ye
Neurobiology of Aging.2024; 134: 57. CrossRef
Imaging Procedure and Clinical Studies of [18F]FP-CIT PET
Changhwan Sung, Seung Jun Oh, Jae Seung Kim
Nuclear Medicine and Molecular Imaging.2024; 58(4): 185. CrossRef
Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort
Beatrice Orso, Pietro Mattioli, Eun-Jin Yoon, Yu Kyeong Kim, Heejung Kim, Jung Hwan Shin, Ryul Kim, Claudio Liguori, Francesco Famà, Andrea Donniaquio, Federico Massa, David Vállez García, Sanne K. Meles, Klaus L. Leenders, Agostino Chiaravalloti, Matteo
Neurological Sciences.2023; 44(9): 3161. CrossRef
Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder
Don Gueu Park, Ju Yeong Kim, Min Seung Kim, Mi Hee Kim, Young-Sil An, Jaerak Chang, Jung Han Yoon
Journal of Neurology.2023; 270(9): 4393. CrossRef
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study
Jung Hwan Shin, Heejung Kim, Yu Kyeong Kim, Eun Jin Yoon, Hyunwoo Nam, Beomseok Jeon, Jee-Young Lee
Translational Neurodegeneration.2023;[Epub] CrossRef
Brain olfactory‐related atrophy in isolated rapid eye movement sleep behavior disorder
Kyung Ah Woo, Heejung Kim, Eun Jin Yoon, Jung Hwan Shin, Hyunwoo Nam, Beomseok Jeon, Yu Kyeong Kim, Jee‐Young Lee
Annals of Clinical and Translational Neurology.2023; 10(12): 2192. CrossRef
Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease
Kyung Ah Woo, Joo Hong Joun, Eun Jin Yoon, Chan Young Lee, Beomseok Jeon, Yu Kyeong Kim, Jee‐Young Lee
Movement Disorders.2023; 38(12): 2291. CrossRef
Altered cerebral perfusion and microstructure in advanced Parkinson’s disease and their associations with clinical features
Zhaoxi Liu, Yiwei Zhang, Han Wang, Dan Xu, Hui You, Zhentao Zuo, Feng Feng
Neurological Research.2022; 44(1): 47. CrossRef
Brain Neuroimaging of Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease: A Systematic Review
Rafail Matzaras, Kuangyu Shi, Artemios Artemiadis, Panagiotis Zis, Georgios Hadjigeorgiou, Axel Rominger, Claudio L.A. Bassetti, Panagiotis Bargiotas
Journal of Parkinson's Disease.2022; 12(1): 69. CrossRef
Odor Identification by Parkinson’s Disease Patients Tested by Using Sniffin’ Sticks versus Natural Spices
Florence Baert, Geertrui Vlaemynck, Jarissa Maselyne, Christophe Matthys, Seyed-Mohammad Fereshtehnejad
Parkinson's Disease.2022; 2022: 1. CrossRef
Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease
Ryul Kim, Heejung Kim, Yu Kyeong Kim, Eun Jin Yoon, Hyun Woo Nam, Beomseok Jeon, Jee‐Young Lee
Movement Disorders.2022; 37(10): 2099. CrossRef
Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder‐Related Metabolic Pattern Expression
Ryul Kim, Jee‐Young Lee, Yu Kyeong Kim, Heejung Kim, Eun Jin Yoon, Jung Hwan Shin, Dallah Yoo, Hyunwoo Nam, Beomseok Jeon
Movement Disorders.2021; 36(8): 1889. CrossRef
Parkinson Disease-Related Brain Metabolic Patterns and Neurodegeneration in Isolated REM Sleep Behavior Disorder
Jung Hwan Shin, Jee-Young Lee, Yu-Kyeong Kim, Eun Jin Yoon, Heejung Kim, Hyunwoo Nam, Beomseok Jeon
Neurology.2021;[Epub] CrossRef
Retina Thickness as a Marker of Neurodegeneration in Prodromal Lewy Body Disease
Jee‐Young Lee, Jeeyun Ahn, Sohee Oh, Joo Young Shin, Yu Kyeong Kim, Hyunwoo Nam, Beomseok Jeon
Movement Disorders.2020; 35(2): 349. CrossRef
Serum TNF-α and neurodegeneration in isolated REM sleep behavior disorder
Ryul Kim, Jee-Young Lee, Han-Joon Kim, Yu Kyeong Kim, Hyunwoo Nam, Beomseok Jeon
Parkinsonism & Related Disorders.2020; 81: 1. CrossRef
Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder
Jung Hwan Shin, Jee-Young Lee, Yu-Kyeong Kim, Sung-A Shin, Heejung Kim, Hyunwoo Nam, Beomseok Jeon
Neurology.2020;[Epub] CrossRef

Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson’s Disease: Young Eun Kim, Han-Joon Kim, Ji Young Yun, Woong-Woo Lee, Hui-Jun Yang, Jong-Min Kim, Beomseok Jeon; J Mov Disord. 2018;11(3):133-138. Published online September 30, 2018; DOI: https://doi.org/10.14802/jmd.18022

8,795 View
152 Download
12 Web of Science
10 Crossref

Abstract PDF

Objective
Musculoskeletal problems are more common in patients with Parkinson’s disease (PD) than in normal elderly, but the impact of musculoskeletal problems on health-related quality of life (HRQoL) in patients with PD is unknown.
Methods
Four hundred consecutive patients with PD were enrolled for the evaluation of musculoskeletal problems and HRQoL. HRQoL was assessed by the 36-Item Short Form Health Survey, which comprised physical health and mental health.
Results
Of the total patients, 265 patients had musculoskeletal problems, and 135 patients did not have musculoskeletal problems. Patients with musculoskeletal problems reported lower levels of HRQoL in terms of physical health than did patients without musculoskeletal problems (p < 0.05). In women, all components of physical health were lower in patients with musculoskeletal problems than in patients without musculoskeletal problems (p < 0.05). Meanwhile, in men, only the bodily pain score of physical health was lower in patients with musculoskeletal problems than in patients without musculoskeletal problems. Mental health and physical health were negatively correlated with depression, Unified Parkinson’s Disease Rating Scale I & II scores, and pain severity from musculoskeletal problems, in that order (p < 0.01 for all).
Conclusion
These results suggest that musculoskeletal problems in patients with PD affect HRQoL significantly, mainly in terms of physical health rather than mental health and especially in women rather than men. Musculoskeletal problems should not be overlooked in the care of patients with PD.

Citations

Citations to this article as recorded by

Assessments scales for the evaluation of health-related quality of life in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy: a systematic review
Maria Lucia Maiuolo, Roberto Giorgini, Maria Grazia Vaccaro, Alessio Facchin, Andrea Quattrone, Aldo Quattrone
Frontiers in Psychology.2024;[Epub] CrossRef
Total knee arthroplasty in patients with Parkinson’s disease: A systematic review and meta-analysis protocol
Guangchen Sun, Hui Yu, Jun Cui, Ming Li, Yuefang Ru
Medicine.2022; 101(52): e32315. CrossRef
Quality of life of older adults in two contrasting neighbourhoods in Accra, Ghana
Dominic A. Alaazi, Devidas Menon, Tania Stafinski, Stephen Hodgins, Gian Jhangri
Social Science & Medicine.2021; 270: 113659. CrossRef
The Efficiency of Spa Rehabilitation in Chronic Ischemic Stroke Patients—Preliminary Reports
Bogumiła Pniak, Justyna Leszczak, Jadwiga Kurczab, Aleksandra Krzemińska, Joanna Pięta, Agnieszka Plis, Ewelina Czenczek-Lewandowska, Agnieszka Guzik
Brain Sciences.2021; 11(4): 501. CrossRef
Sex-specific effects of subthalamic nucleus stimulation on pain in Parkinson’s disease
Olga Khazen, Marisa DiMarzio, Kelsey Platanitis, Heather C. Grimaudo, Maria Hancu, Miriam M. Shao, Michael D. Staudt, Lucy Maguire, Vishad V. Sukul, Jennifer Durphy, Era K. Hanspal, Octavian Adam, Eric Molho, Julie G. Pilitsis
Journal of Neurosurgery.2021; 135(2): 629. CrossRef
An overview of pain in Parkinson's disease
Yi-Cheng Tai, Chin-Hsien Lin
Clinical Parkinsonism & Related Disorders.2020; 2: 1. CrossRef
Clinical Perspectives of Parkinson's Disease for Ophthalmologists, Otorhinolaryngologists, Cardiologists, Dentists, Gastroenterologists, Urologists, Physiatrists, and Psychiatrists
Ji-Hyun Choi, Jong-Min Kim, Hee Kyung Yang, Hyo-Jung Lee, Cheol Min Shin, Seong Jin Jeong, Won-Seok Kim, Ji Won Han, In-Young Yoon, Yoo Sung Song, Yun Jung Bae
Journal of Korean Medical Science.2020;[Epub] CrossRef
Parkinson's Disease Is Associated with Increased Complications, Readmission Rates, and Costs of Care after Total Hip Arthroplasty: A Matched-Cohort Analysis
Simon Katz, Kevin B. Marchand, Rushabh M. Vakharia, Hiba Anis, Nipun Sodhi, Nicolas S. Piuzzi, Michael A. Mont, Martin W. Roche
The Journal of Hip Surgery.2020; 4(03): 149. CrossRef
Chronic Pain Treatment Strategies in Parkinson’s Disease
Amber Edinoff, Niro Sathivadivel, Timothy McBride, Allyson Parker, Chikezie Okeagu, Alan D. Kaye, Adam M. Kaye, Jessica S. Kaye, Rachel J. Kaye, Meeta M. Sheth, Omar Viswanath, Ivan Urits
Neurology International.2020; 12(3): 61. CrossRef
Sex differences in the short-term and long-term effects of subthalamic nucleus stimulation in Parkinson's disease
Ryul Kim, Dallah Yoo, Ji-Hyun Choi, Jung Hwan Shin, Sangmin Park, Han-Joon Kim, Sun Ha Paek, Beomseok Jeon
Parkinsonism & Related Disorders.2019; 68: 73. CrossRef

A Patient with Myotonic Dystrophy Type 1 Presenting as Parkinsonism: Ji-Hyun Choi, Jee-Young Lee, Han-Joon Kim, Beomseok Jeon; J Mov Disord. 2018;11(3):145-148. Published online September 30, 2018; DOI: https://doi.org/10.14802/jmd.18028

6,140 View
106 Download
1 Web of Science

Abstract PDF: The current body of literature contains 5 reports of myotonic dystrophy (DM) with parkinsonism: 4 reports of DM type 2 and 1 report of clinically suspected DM type 1. To date, there have been no genetically proven cases of DM type 1 with parkinsonism. Here, we report the first case of genetically proven DM type 1 and parkinsonism that developed ahead of muscle symptoms with bilateral putaminal, presynaptic dopaminergic deficits on imaging. A 54-year-old female patient presented with bradykinesia, axial and bilateral limb rigidity, stooped posture, and hypomimia, which did not respond to levodopa. At age 56, she developed neck flexion weakness. Examination showed bilateral facial weakness, percussion and grip myotonia, and electromyography confirmed myotonic discharges. A genetic study of DM type 1 showed a DMPK mutation. At age 58, gait freezing, postural instability, and frequent falling developed and did not respond to increasing doses of levodopa. At age 59, the patient died from asphyxia.

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial: Aryun Kim, Young Eun Kim, Ji Young Yun, Han-Joon Kim, Hui-Jun Yang, Woong-Woo Lee, Chae Won Shin, Hyeyoung Park, Yu Jin Jung, Ahro Kim, Yoon Kim, Mihee Jang, Beomseok Jeon; J Mov Disord. 2018;11(2):65-71. Published online May 30, 2018; DOI: https://doi.org/10.14802/jmd.18005

10,152 View
260 Download
12 Web of Science
15 Crossref

Abstract PDF Supplementary Material

Objective
We examined whether amantadine can prevent the development of dyskinesia.
Methods
Patients with drug-naïve Parkinson’s disease (PD), younger than 70 years of age and in the early stage of PD (Hoehn and Yahr scale < 3), were recruited from April 2011 to December 2014. The exclusion criteria included the previous use of antiparkinsonian medication, the presence of dyskinesia, significant psychological disorders, and previous history of a hypersensitivity reaction. Patients were consecutively assigned to one of 3 treatment groups in an open label fashion: Group A-1, amantadine first and then levodopa when needed; Group A-2, amantadine first, dopamine agonist when needed, and then levodopa; and Group B, dopamine agonist first and then levodopa when needed. The primary endpoint was the development of dyskinesia, which was analyzed by the Kaplan-Meier survival rate.
Results
A total of 80 patients were enrolled: Group A-1 (n = 27), Group A-2 (n = 27), and Group B (n = 26). Twenty-four patients were excluded from the analysis due to the following: withdrawal of amantadine or dopamine agonist (n = 9), alternative diagnosis (n = 2), withdrawal of consent (n = 1), and breach in the protocol (n = 12). After exclusion, 5 of the 56 (8.93%) patients developed dyskinesia. Patients in Group A-1 and A-2 tended to develop dyskinesia less often than those in Group B (cumulative survival rates of 0.933, 0.929, and 0.700 for A-1, A-2, and B, respectively; p = 0.453).
Conclusion
Amantadine as an initial treatment may decrease the incidence of dyskinesia in patients with drug-naïve PD.

Citations

Citations to this article as recorded by

Exploring causal effects of sarcopenia on risk and progression of Parkinson disease by Mendelian randomization
Tao Wang, Jiaquan Geng, Xi Zeng, Ruijiang Han, Young Eun Huh, Jiajie Peng
npj Parkinson's Disease.2024;[Epub] CrossRef
Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease
Sangmin Park, Jung Hwan Shin, Seung Ho Jeon, Chan Young Lee, Han-Joon Kim, Beomseok Jeon
Journal of Movement Disorders.2023; 16(2): 224. CrossRef
Polypharmazie bei der Behandlung von Parkinsonsymptomen: eine Nutzen-Risiko Abwägung
J. Bedarf, I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner
DGNeurologie.2023; 6(6): 504. CrossRef
Role of glutamate receptor complex in the organism. Ligands of NMDA receptors in neurodegenerative processes – a modern state of the problem
Vladimir D. Dergachev, Ekaterina E. Yakovleva, Eugenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov
Reviews on Clinical Pharmacology and Drug Therapy.2022; 20(1): 17. CrossRef
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat
Imane Frouni, Woojin Kang, Dominique Bédard, Sébastien Belliveau, Cynthia Kwan, Shadi Hadj-Youssef, Élodie Bourgeois-Cayer, Leanne Ohlund, Lekha Sleno, Adjia Hamadjida, Philippe Huot
European Journal of Pharmacology.2022; 929: 175090. CrossRef
Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19
E.A. Katunina
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(4): 101. CrossRef
Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review
Michał Hutny, Jagoda Hofman, Aleksandra Klimkowicz-Mrowiec, Agnieszka Gorzkowska
Journal of Clinical Medicine.2021; 10(19): 4377. CrossRef
Neuroinflammation and blood–brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets
Suraj Sulhan, Kristopher A. Lyon, Lee A. Shapiro, Jason H. Huang
Journal of Neuroscience Research.2020; 98(1): 19. CrossRef
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
Sohaila AlShimemeri, Susan H Fox, Naomi P Visanji
Expert Opinion on Emerging Drugs.2020; 25(2): 131. CrossRef
Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD)
Michelle Ann C. Sy, Hubert H. Fernandez
Neurotherapeutics.2020; 17(4): 1331. CrossRef
Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
Jing Liu, Fei Xu, Zhiyan Nie, Lei Shao
Frontiers in Cellular and Infection Microbiology.2020;[Epub] CrossRef
Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold?
Susan H. Fox, Jonathan M. Brotchie
European Journal of Neuroscience.2019; 49(3): 399. CrossRef
Polypharmacy in Parkinson’s disease: risks and benefits with little evidence
I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner
Journal of Neural Transmission.2019; 126(7): 871. CrossRef
Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism
Imane Frouni, Adjia Hamadjida, Cynthia Kwan, Dominique Bédard, Vaidehi Nafade, Fleur Gaudette, Stephen G. Nuara, Jim C. Gourdon, Francis Beaudry, Philippe Huot
Neuropharmacology.2019; 158: 107725. CrossRef
Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update
Valentina Leta, Peter Jenner, K. Ray Chaudhuri, Angelo Antonini
Expert Opinion on Drug Safety.2019; 18(12): 1203. CrossRef

Myotonia Congenita Can Be Mistaken as Paroxysmal Kinesigenic Dyskinesia: Aryun Kim, Mihee Jang, Han-Joon Kim, Yoon Kim, Dae-Seong Kim, Jin-Hong Shin, Beomseok Jeon; J Mov Disord. 2018;11(1):49-51. Published online January 23, 2018; DOI: https://doi.org/10.14802/jmd.17056

7,815 View
134 Download
4 Web of Science
4 Crossref

PDF

Citations

Citations to this article as recorded by

Genetic updates on paroxysmal dyskinesias
James Y. Liao, Philippe A. Salles, Umar A. Shuaib, Hubert H. Fernandez
Journal of Neural Transmission.2021; 128(4): 447. CrossRef
A Japanese family with primary familial brain calcification presenting with paroxysmal kinesigenic dyskinesia - A comprehensive mutational analysis-
Akihiko Mitsutake, Takashi Matsukawa, Kristine Joyce L. Porto, Tatsuya Sato, Junko Katsumata, Tomonari Seki, Risa Maekawa, Takuto Hideyama, Masaki Tanaka, Hiroyuki Ishiura, Tatsushi Toda, Shoji Tsuji, Yasushi Shiio
Journal of the Neurological Sciences.2020; 418: 117091. CrossRef
Paroxysmal movement disorders – practical update on diagnosis and management
Claudio M. De Gusmao, Laura Silveira-Moriyama
Expert Review of Neurotherapeutics.2019; 19(9): 807. CrossRef
The study of exercise tests in paroxysmal kinesigenic dyskinesia
Hai-Yan Zhou, Fei-Xia Zhan, Wo-Tu Tian, Chao Zhang, Yan Wang, Ze-Yu Zhu, Xiao-Li Liu, Yang-Qi Xu, Xing-Hua Luan, Xiao-Jun Huang, Sheng-Di Chen, Li Cao
Clinical Neurophysiology.2018; 129(11): 2435. CrossRef

Validation of the Conversion between the Mini-Mental State Examination and Montreal Cognitive assessment in Korean Patients with Parkinson’s Disease: Ryul Kim, Han-Joon Kim, Aryun Kim, Mi-Hee Jang, Hyun Jeong Kim, Beomseok Jeon; J Mov Disord. 2018;11(1):30-34. Published online January 11, 2018; DOI: https://doi.org/10.14802/jmd.17038

9,682 View
255 Download
13 Web of Science
18 Crossref

Abstract PDF

Objective
Two conversion tables between the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) have recently been established for Parkinson’s disease (PD). This study aimed to validate them in Korean patients with PD and to evaluate whether they could be influenced by educational level.
Methods
A total of 391 patients with PD who undertook both the Korean MMSE and the Korean MoCA during the same session were retrospectively assessed. The mean, median, and root mean squared error (RMSE) of the difference between the true and converted MMSE scores and the intraclass correlation coefficient (ICC) were calculated according to educational level (6 or fewer years, 7–12 years, or 13 or more years).
Results
Both conversions had a median value of 0, with a small mean and RMSE of differences, and a high correlation between the true and converted MMSE scores. In the classification according to educational level, all groups had roughly similar values of the median, mean, RMSE, and ICC both within and between the conversions.
Conclusion
Our findings suggest that both MMSE-MoCA conversion tables are useful instruments for transforming MoCA scores into converted MMSE scores in Korean patients with PD, regardless of educational level. These will greatly enhance the utility of the existing cognitive data from the Korean PD population in clinical and research settings.

Citations

Citations to this article as recorded by

Heterogeneous factors influence social cognition across diverse settings in brain health and age-related diseases
Sol Fittipaldi, Agustina Legaz, Marcelo Maito, Hernan Hernandez, Florencia Altschuler, Veronica Canziani, Sebastian Moguilner, Claire M. Gillan, Josefina Castillo, Patricia Lillo, Nilton Custodio, José Alberto Avila-Funes, Juan Felipe Cardona, Andrea Slac
Nature Mental Health.2024; 2(1): 63. CrossRef
Application of machine learning models on predicting the length of hospital stay in fragility fracture patients
Chun-Hei Lai, Prudence Kwan-Lam Mok, Wai-Wang Chau, Sheung-Wai Law
BMC Medical Informatics and Decision Making.2024;[Epub] CrossRef
Gaze Scanning on Mid-Block Sidewalks by Pedestrians With Homonymous Hemianopia With or Without Spatial Neglect
Shrinivas Pundlik, Matteo Tomasi, Kevin E. Houston, Ayush Kumar, Prerana Shivshanker, Alex R. Bowers, Eli Peli, Gang Luo
Investigative Ophthalmology & Visual Science.2024; 65(8): 46. CrossRef
Effects of nonimmersive virtual reality using Wii-Fit exercises on balance and cognition in Parkinson disease: A meta-analysis
Fouzia Hussain, Sumaira Farooqui, Amna Aamir Khan, Muhammad Usman Khan, Muhammad Abid Khan, Ahad Hasan
Medicine.2024; 103(30): e38940. CrossRef
Gaze Scanning at Street Crossings by Pedestrians With Homonymous Hemianopia With and Without Hemispatial Neglect
Shrinivas Pundlik, Matteo Tomasi, Kevin E. Houston, Ayush Kumar, Prerana Shivshanker, Alex R. Bowers, Eli Peli, Gang Luo
Investigative Opthalmology & Visual Science.2023; 64(14): 26. CrossRef
Comparative study of two Chinese versions of Montreal Cognitive Assessment for Screening of Mild Cognitive Impairment
Yu-Yuan Huang, Shu-Xia Qian, Qiao-Bing Guan, Ke-Liang Chen, Qian-Hua Zhao, Jia-Hong Lu, Qi-Hao Guo
Applied Neuropsychology: Adult.2021; 28(1): 88. CrossRef
Conversion between Mini‐Mental State Examination and Montreal Cognitive Assessment scores in older adults undergoing selective surgery using Rasch analysis
Xiaoying Chen, Huangliang Wen, Jinni Wang, Yayan Yi, Jialan Wu, Xiaoyan Liao
Journal of Advanced Nursing.2021; 77(2): 729. CrossRef
Converting from the Montreal Cognitive Assessment to the Mini-Mental State Examination-2
Hwabeen Yang, Daehyuk Yim, Moon Ho Park, Antony Bayer
PLOS ONE.2021; 16(7): e0254055. CrossRef
Validation of Four Methods for Converting Scores on the Montreal Cognitive Assessment to Scores on the Mini-Mental State Examination-2
Sung Hoon Kang, Moon Ho Park
Dementia and Neurocognitive Disorders.2021; 20(4): 41. CrossRef
Կոգնիտիվ վիճակի գնահատման Mini-Mental State Examination (MMSE) սանդղակի հայերեն տարբերակի ադապտացում և վալիդացում
Մ.Ա. Իսայան, Հ.Ա. Հովակիմյան, Լ.Վ. Վարդանյան, Ս.Գ. Խաչատրյան, Զ.Դ. Թավադյան
Armenian Journal of Health & Medical Sciences.2021; : 27. CrossRef
Determinant of Quality of Life in Patients with Chronic Cerebral Infarct
Yujin Lee, Joon Sung Kim, Bo Young Hong, Jung Geun Park, Jae Wan Yoo, Kyoung Bo Lee, Tae-Woo Kim, Seong Hoon Lim
Brain & Neurorehabilitation.2020;[Epub] CrossRef
Concordance of Mini-Mental State Examination, Montreal Cognitive Assessment and Parkinson Neuropsychometric Dementia Assessment in the classification of cognitive performance in Parkinson's disease
Jannik Florian Scheffels, Leon Fröhlich, Elke Kalbe, Josef Kessler
Journal of the Neurological Sciences.2020; 412: 116735. CrossRef
Hand motor functions on the presence of red fluorescent dental biofilm in older community-dwelling Koreans
Na-Ri Shin, Yeo-Jin Yi, Jun-Seon Choi
Photodiagnosis and Photodynamic Therapy.2019; 28: 120. CrossRef
Is the modified Mann Assessment of Swallowing Ability useful for assessing dysphagia in patients with mild to moderate dementia?
Eun Kyu Ji, Hae Hyun Wang, Sung June Jung, Kyoung Bo Lee, Joon Sung Kim, Bo Young Hong, Seong Hoon Lim
Journal of Clinical Neuroscience.2019; 70: 169. CrossRef
The Changes for Strength of Oropharyngeal Muscles in Patients with Dementia and Dysphagia
Eun Kyu Ji, Hae Hyun Wang, Sung June Jung, Kyoung Bo Lee, Joon Sung Kim, Bo Young Hong, Tae-Woo Kim, Seong Hoon Lim
Brain & Neurorehabilitation.2019;[Epub] CrossRef
Konversionen von kognitiven Screenings
J. F. Scheffels, H. Kräling, E. Kalbe, J. Kessler
Der Nervenarzt.2018; 89(12): 1371. CrossRef
Manual Dexterity and Aging: A Pilot Study Disentangling Sensorimotor From Cognitive Decline
Loic Carment, Abir Abdellatif, Carmelo Lafuente-Lafuente, Sylvie Pariel, Marc A. Maier, Joël Belmin, Påvel G. Lindberg
Frontiers in Neurology.2018;[Epub] CrossRef
Validation of MoCA-MMSE Conversion Scales in Korean Patients with Cognitive Impairments
Young Ik Jung, Eun Hye Jeong, Heejin Lee, Junghee Seo, Hyun-Jeong Yu, Jin Y. Hong, Mun Kyung Sunwoo
Dementia and Neurocognitive Disorders.2018; 17(4): 148. CrossRef

Validation of the Korean Version of the Scale for Outcomes in Parkinson’s Disease-Autonomic: Ji-Young Kim, In-Uk Song, Seong-Beom Koh, Tae-Beom Ahn, Sang Jin Kim, Sang-Myung Cheon, Jin Whan Cho, Yun Joong Kim, Hyeo-Il Ma, Mee-Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, Han-Joon Kim, Young-Hee Sung, Do Young Kwon, Jae-Hyeok Lee, Jee-Young Lee, Ji Sun Kim, Ji Young Yun, Hee Jin Kim, Jin Young Hong, Mi-Jung Kim, Jinyoung Youn, Ji Seon Kim, Eung Seok Oh, Hui-Jun Yang, Won Tae Yoon, Sooyeoun You, Kyum-Yil Kwon, Hyung-Eun Park, Su-Yun Lee, Younsoo Kim, Hee-Tae Kim, Joong-Seok Kim; J Mov Disord. 2017;10(1):29-34. Published online January 18, 2017; DOI: https://doi.org/10.14802/jmd.16057

15,933 View
373 Download
31 Web of Science
30 Crossref

Abstract PDF Supplementary Material

Objective
Autonomic symptoms are commonly observed in patients with Parkinson’s disease (PD) and often limit the activities of daily living. The Scale for Outcomes in Parkinson’s disease-Autonomic (SCOPA-AUT) was developed to evaluate and quantify autonomic symptoms in PD. The goal of this study was to translate the original SCOPA-AUT, which was written in English, into Korean and to evaluate its reliability and validity for Korean PD patients.
Methods
For the translation, the following processes were performed: forward translation, backward translation, expert review, pretest of the pre-final version and development of the final Korean version of SCOPA-AUT (K-SCOPA-AUT). In total, 127 patients with PD from 31 movement disorder clinics of university-affiliated hospitals in Korea were enrolled in this study. All patients were assessed using the K-SCOPA-AUT and other motor, non-motor, and quality of life scores. Test-retest reliability for the K-SCOPA-AUT was assessed over a time interval of 10−14 days.
Results
The internal consistency and reliability of the K-SCOPA-AUT was 0.727 as measured by the mean Cronbach’s α-coefficient. The test-retest correlation reliability was 0.859 by the Guttman split-half coefficient. The total K-SCOPA-AUT score showed a positive correlation with other non-motor symptoms [the Korean version of non-motor symptom scale (K-NMSS)], activities of daily living (Unified Parkinson’s Disease Rating Scale part II) and quality of life [the Korean version of Parkinson’s Disease Quality of Life 39 (K-PDQ39)].
Conclusion
The K-SCOPA-AUT had good reliability and validity for the assessment of autonomic dysfunction in Korean PD patients. Autonomic symptom severities were associated with many other motor and non-motor impairments and influenced quality of life.

Citations

Citations to this article as recorded by

Baseline prevalence and longitudinal assessment of autonomic dysfunction in early Parkinson’s disease
Lanqing Yang, Huan Gao, Min Ye
Journal of Neural Transmission.2024; 131(2): 127. CrossRef
Association Between Gait and Dysautonomia in Patients With De Novo Parkinson’s Disease: Forward Gait Versus Backward Gait
Seon-Min Lee, Mina Lee, Eun Ji Lee, Rae On Kim, Yongduk Kim, Kyum-Yil Kwon
Journal of Movement Disorders.2023; 16(1): 59. CrossRef
Beyond shallow feelings of complex affect: Non-motor correlates of subjective emotional experience in Parkinson’s disease
Claudia Carricarte Naranjo, Claudia Sánchez Luaces, Ivonne Pedroso Ibáñez, Andrés Machado, Hichem Sahli, María Antonieta Bobes, Vincenzo De Luca
PLOS ONE.2023; 18(2): e0281959. CrossRef
Autonomic function and motor subtypes in Parkinson’s disease: a multicentre cross-sectional study
Si-Chun Gu, Rong Shi, Chen Gao, Xiao-Lei Yuan, You Wu, Zhen-Guo Liu, Chang-De Wang, Shao-Rong Zhao, Xiqun Chen, Can-Xing Yuan, Qing Ye
Scientific Reports.2023;[Epub] CrossRef
Clinical manifestation of patients with isolated rapid eye movement sleep behavior disorder after modest-to-long disease duration
Jung Kyung Hong, Jong-Min Kim, Ki-woong Kim, Ji Won Han, Soyeon Ahn, In-Young Yoon
Sleep.2022;[Epub] CrossRef
Associations of cognitive dysfunction with motor and non-motor symptoms in patients with de novo Parkinson’s disease
Kyum-Yil Kwon, Suyeon Park, Rae On Kim, Eun Ji Lee, Mina Lee
Scientific Reports.2022;[Epub] CrossRef
Autonomic dysfunction in Parkinson's disease: Results from the Faroese Parkinson's disease cohort
Aksel Berg, Sára Bech, Jan Aasly, Matthew J. Farrer, Maria Skaalum Petersen
Neuroscience Letters.2022; 785: 136789. CrossRef
Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: A systematic review and meta-analysis
Fang-Fei Li, Yu-Sha Cui, Rui Yan, Shuang-Shuang Cao, Tao Feng
Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
White matter tract-specific microstructural disruption is associated with depressive symptoms in isolated RBD
Jung-Ick Byun, Seunghwan Oh, Jun-Sang Sunwoo, Jung-Won Shin, Tae-Joon Kim, Jin-Sun Jun, Han-Joon Kim, Won Chul Shin, Joon-Kyung Seong, Ki-Young Jung
NeuroImage: Clinical.2022; 36: 103186. CrossRef
Comparison of disease progression between brain-predominant Parkinson's disease versus Parkinson's disease with body-involvement phenotypes
Dong-Woo Ryu, Sang-Won Yoo, Yoon-Sang Oh, Kwang-Soo Lee, Seunggyun Ha, Joong-Seok Kim
Neurobiology of Disease.2022; 174: 105883. CrossRef
Corneal confocal microscopy differentiates patients with Parkinson’s disease with and without autonomic involvement
Ning-Ning Che, Shuai Chen, Qiu-Huan Jiang, Si-Yuan Chen, Zhen-Xiang Zhao, Xue Li, Rayaz A. Malik, Jian-Jun Ma, Hong-Qi Yang
npj Parkinson's Disease.2022;[Epub] CrossRef
Association of Nucleus Basalis of Meynert Functional Connectivity and Cognition in Idiopathic Rapid-Eye-Movement Sleep Behavior Disorder
Jung-Ick Byun, Kwang Su Cha, Minah Kim, Woo-Jin Lee, Han Sang Lee, Jun-Sang Sunwoo, Jung-Won Shin, Tae-Joon Kim, Jin-Sun Jun, Han-Joon Kim, Won Chul Shin, Carlos H. Schenck, Sang Kun Lee, Ki-Young Jung
Journal of Clinical Neurology.2022; 18(5): 562. CrossRef
White Matter Tract-Specific Microstructural Disruption is Associated with Depressive Symptoms in Isolated Rbd
Jung-Ick Byun, Seunghwan Oh, Jun-Sang Sunwoo, Jung-Won Shin, Tae-Joon Kim, Jin-Sun Jun, Han-Joon Kim, Won Chul Shin, Joon-Kyung Seong, Ki-Young Jung
SSRN Electronic Journal .2022;[Epub] CrossRef
Altered insular functional connectivity in isolated REM sleep behavior disorder: a data-driven functional MRI study
Jung-Ick Byun, Kwang Su Cha, Minah Kim, Woo-Jin Lee, Han Sang Lee, Jun-Sang Sunwoo, Jung-Won Shin, Tae-Joon Kim, Jangsup Moon, Soon-Tae Lee, Keun-Hwa Jung, Kon Chu, Man-Ho Kim, Han-Joon Kim, Won Chul Shin, Sang Kun Lee, Ki-Young Jung
Sleep Medicine.2021; 79: 88. CrossRef
Association of fall risk factors and non-motor symptoms in patients with early Parkinson’s disease
Kyum-Yil Kwon, Suyeon Park, Eun Ji Lee, Mina Lee, Hyunjin Ju
Scientific Reports.2021;[Epub] CrossRef
Impact of motor subtype on non‐motor symptoms and fall‐related features in patients with early Parkinson's disease
Kyum‐Yil Kwon, Eun Ji Lee, Mina Lee, Hyunjin Ju, Kayeong Im
Geriatrics & Gerontology International.2021; 21(5): 416. CrossRef
Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson’s disease
Minkyeong Kim, Seulki Yoo, Doyeon Kim, Jin Whan Cho, Ji Sun Kim, Jong Hyun Ahn, Jun Kyu Mun, Inyoung Choi, Seung-Kyun Lee, Jinyoung Youn
Neurological Sciences.2021; 42(12): 5297. CrossRef
Clinical Assessment Scales in Autonomic Nervous System Disorders
Eun Bin Cho, Ki-Jong Park
Journal of the Korean Neurological Association.2021; 39(2 Suppl): 60. CrossRef
Cardiac sympathetic burden reflects Parkinson disease burden, regardless of high or low orthostatic blood pressure changes
Sang-Won Yoo, Joong-Seok Kim, Yoon-Sang Oh, Dong-Woo Ryu, Seunggyun Ha, Ji-Yeon Yoo, Kwang-Soo Lee
npj Parkinson's Disease.2021;[Epub] CrossRef
Understanding fatigue in progressive supranuclear palsy
Jong Hyeon Ahn, Joomee Song, Dong Yeong Lee, Jinyoung Youn, Jin Whan Cho
Scientific Reports.2021;[Epub] CrossRef
Validation of the Korean version of the composite autonomic symptom scale 31 in patients with Parkinson’s disease
Jong Hyeon Ahn, Jin Myoung Seok, Jongkyu Park, Heejeong Jeong, Younsoo Kim, Joomee Song, Inyoung Choi, Jin Whan Cho, Ju-Hong Min, Byoung Joon Kim, Jinyoung Youn, Antonina Luca
PLOS ONE.2021; 16(10): e0258897. CrossRef
Cardiac Autonomic Dysfunction Is Associated with Severity of REM Sleep without Atonia in Isolated REM Sleep Behavior Disorder
Sooyeoun You, Kyoung Sook Won, Keun Tae Kim, Hyang Woon Lee, Yong Won Cho
Journal of Clinical Medicine.2021; 10(22): 5414. CrossRef
Characteristics of Autonomic Dysfunction in Parkinson’s Disease: A Large Chinese Multicenter Cohort Study
Zhou Zhou, Xiaoting Zhou, Xiaoxia Zhou, Yaqin Xiang, Liping Zhu, Lixia Qin, Yige Wang, Hongxu Pan, Yuwen Zhao, Qiying Sun, Qian Xu, Xinyin Wu, Xinxiang Yan, Jifeng Guo, Beisha Tang, Zhenhua Liu
Frontiers in Aging Neuroscience.2021;[Epub] CrossRef
Autonomic Dysfunction in Parkinson's Disease: Results from the Faroese Parkinson's Disease Cohort
Aksel Kambsskarð Berg, Sára Bech, Jan O. Aasly, Matthew J. Farrer, Maria Skaalum Petersen
SSRN Electronic Journal .2021;[Epub] CrossRef
Subtypes of Sleep Disturbance in Parkinson's Disease Based on the Cross-Culturally Validated Korean Version of Parkinson's Disease Sleep Scale-2
Hui-Jun Yang, Han-Joon Kim, Seong-Beom Koh, Joong-Seok Kim, Tae-Beom Ahn, Sang-Myung Cheon, Jin Whan Cho, Yoon-Joong Kim, Hyeo-Il Ma, Mee Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, In-Uk Song, Ji-Young Kim, Young-Hee Sung, Do You
Journal of Clinical Neurology.2020; 16(1): 66. CrossRef
Risk Factors for Falls in Patients with de novo Parkinson’s Disease: A Focus on Motor and Non-Motor Symptoms
Kyum-Yil Kwon, Mina Lee, Hyunjin Ju, Kayeong Im
Journal of Movement Disorders.2020; 13(2): 142. CrossRef
Peripheral Blood Inflammatory Cytokines in Idiopathic REM Sleep Behavior Disorder
Ryul Kim, Jin‐Sun Jun, Han‐Joon Kim, Ki‐Young Jung, Yong‐Won Shin, Tae‐Won Yang, Keun Tae Kim, Tae‐Joon Kim, Jung‐Ick Byun, Jun‐Sang Sunwoo, Beomseok Jeon
Movement Disorders.2019; 34(11): 1739. CrossRef
Urinary Dysfunctions and Post-Void Residual Urine in Typical and Atypical Parkinson Diseases
Yang-Hyun Lee, Jee-Eun Lee, Dong-Woo Ryu, Yoon-Sang Oh, Kwang-Soo Lee, Sung-Hoo Hong, Joong-Seok Kim
Journal of Parkinson's Disease.2018; 8(1): 145. CrossRef
Rasch Analysis of the Clinimetric Properties of the Korean Dizziness Handicap Inventory in Patients with Parkinson Disease
Da-Young Lee, Hui-Jun Yang, Dong-Seok Yang, Jin-Hyuk Choi, Byoung-Soo Park, Ji-Yun Park
Research in Vestibular Science.2018; 17(4): 152. CrossRef
Clinical Characteristics of Parkinson’s Disease Developed from Essential Tremor
Dong-Woo Ryu, Si-Hoon Lee, Yoon-Sang Oh, Jae-Young An, Jeong-Wook Park, In-Uk Song, Kwang-Soo Lee, Joong-Seok Kim
Journal of Parkinson's Disease.2017; 7(2): 369. CrossRef

Survival of Korean Huntington’s Disease Patients: Han-Joon Kim, Chae-Won Shin, Beomseok Jeon, Hyeyoung Park; J Mov Disord. 2016;9(3):166-170. Published online September 21, 2016; DOI: https://doi.org/10.14802/jmd.16022

16,282 View
154 Download
13 Web of Science
12 Crossref

Abstract PDF

Objective
The survival of Huntington’s disease (HD) patients is reported to be 15–20 years. However, most studies on the survival of HD have been conducted in patients without genetic confirmation with the possible inclusion of non-HD patients, and all studies have been conducted in Western countries. The survival of patients with HD in East Asia, where its prevalence is 10–50-fold lower compared with Western populations, has not yet been reported.
Methods
Forty-seven genetically confirmed Korean HD patients from independent families were included in this retrospective medical record review study.
Results
The mean age at onset among the 47 patients was 46.1 ± 14.0 years. At the time of data collection, 25 patients had died, and these patients had a mean age at death of 57.8 ± 13.7 years. The Kaplan-Meier estimate of the median survival from onset in the 47 patients was 14.5 years (95% confidence interval: 12.3–16.6). None of the following factors were associated with the survival time in the univariate Cox regression analysis: gender, age at onset, normal CAG repeat size, mutant CAG repeat size, and the absence or presence of non-motor symptoms at onset.
Conclusion
This is the first Asian study on survival in HD patients. Survival in Korean HD patients may be shorter than that reported for Western populations, or at least is in the lower range of expected survival. A larger longitudinal observation study is needed to confirm the results found in this study.

Citations

Citations to this article as recorded by

Analysis of HTT CAG repeat expansion among healthy individuals and patients with chorea in Korea
Ryul Kim, Moon-Woo Seong, Bumjo Oh, Ho Seop Shin, Jee-Soo Lee, Sangmin Park, Mihee Jang, Beomseok Jeon, Han-Joon Kim, Jee-Young Lee
Parkinsonism & Related Disorders.2024; 118: 105930. CrossRef
Clinical and Genetic Characteristics Associated With Survival Outcome in Late-Onset Huntington’s Disease in South Korea
Yun Su Hwang, Sungyang Jo, Gu-Hwan Kim, Jee-Young Lee, Ho-Sung Ryu, Eungseok Oh, Seung-Hwan Lee, Young Seo Kim, Sun Ju Chung
Journal of Clinical Neurology.2024; 20(4): 394. CrossRef
A Practical Guide for Clinical Approach to Patients With Huntington’s Disease in Korea
Chaewon Shin, Ryul Kim, Dallah Yoo, Eungseok Oh, Jangsup Moon, Minkyeong Kim, Jee-Young Lee, Jong-Min Kim, Seong-Beom Koh, Manho Kim, Beomseok Jeon
Journal of Movement Disorders.2024; 17(2): 138. CrossRef
Increased 10-Year Prevalence of Huntington’s Disease in South Korea: An Analysis of Medical Expenditure Through the National Healthcare System
Chan Young Lee, Jun-soo Ro, Hyemin Jung, Manho Kim, Beomseok Jeon, Jee-Young Lee
Journal of Clinical Neurology.2023; 19(2): 147. CrossRef
Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach
Jinnie Ko, Hannah Furby, Xiaoye Ma, Jeffrey D. Long, Xiao-Yu Lu, Diana Slowiejko, Rita Gandhy
Frontiers in Neurology.2023;[Epub] CrossRef
Survival in Huntington’s disease and other young‐onset dementias
Samantha M. Loi, Paraskevi Tsoukra, Emily Sun, Zhibin Chen, Pierre Wibawa, Maria di Biase, Sarah Farrand, Dhamidhu Eratne, Wendy Kelso, Andrew Evans, Mark Walterfang, Dennis Velakoulis
International Journal of Geriatric Psychiatry.2023;[Epub] CrossRef
Functional Intercellular Transmission of miHTT via Extracellular Vesicles: An In Vitro Proof-of-Mechanism Study
Roberto D. V. S. Morais, Marina Sogorb-González, Citlali Bar, Nikki C. Timmer, M. Leontien Van der Bent, Morgane Wartel, Astrid Vallès
Cells.2022; 11(17): 2748. CrossRef
Huntington's disease: Mortality and risk factors in an Australian cohort
Emily Sun, Matthew Kang, Pierre Wibawa, Vivian Tsoukra, Zhibin Chen, Sarah Farrand, Dhamidhu Eratne, Wendy Kelso, Andrew Evans, Mark Walterfang, Dennis Velakoulis, Samantha M. Loi
Journal of the Neurological Sciences.2022; 442: 120437. CrossRef
Huntington’s disease in Turkey: genetic counseling, clinical features, and outcome
Yesim Sucullu Karadag, Busranur Erozan Cavdarli, Rabia Nazik Yuksel
Neurological Research.2021; 43(5): 381. CrossRef
Validation of diagnostic codes and epidemiologic trends of Huntington disease: a population-based study in Navarre, Spain
Esther Vicente, Ainara Ruiz de Sabando, Fermín García, Itziar Gastón, Eva Ardanaz, María A. Ramos-Arroyo
Orphanet Journal of Rare Diseases.2021;[Epub] CrossRef
Epidemiology of Huntington disease in Cyprus: A 20‐year retrospective study
C.A. Demetriou, A. Heraclides, C. Salafori, G.A. Tanteles, K. Christodoulou, Y. Christou, E. Zamba‐Papanicolaou
Clinical Genetics.2018; 93(3): 656. CrossRef
Population-specific genetic modification of Huntington's disease in Venezuela
Michael J. Chao, Kyung-Hee Kim, Jun Wan Shin, Diane Lucente, Vanessa C. Wheeler, Hong Li, Jared C. Roach, Leroy Hood, Nancy S. Wexler, Laura B. Jardim, Peter Holmans, Lesley Jones, Michael Orth, Seung Kwak, Marcy E. MacDonald, James F. Gusella, Jong-Min L
PLOS Genetics.2018; 14(5): e1007274. CrossRef

Dural Arteriovenous Fistula-Associated Reversible Parkinsonism with Presynaptic Dopaminergic Loss: Hang Rai Kim, Jee-Young Lee, Yu Kyeong Kim, Hyeyoung Park, Han-Joon Kim, Young-Je Son, Beom Seok Jeon; J Mov Disord. 2015;8(3):141-143. Published online September 10, 2015; DOI: https://doi.org/10.14802/jmd.15021

14,203 View
71 Download
6 Web of Science
7 Crossref

PDF

Citations

Citations to this article as recorded by

The Multifocal Dural Arteriovenous Fistula Presumed to Present as a Progressive Cognitive Impairment
Seunghee Na, Seung-Keun Lee, Eek-Sung Lee
Dementia and Neurocognitive Disorders.2024; 23(1): 67. CrossRef
A case of Parkinson's disease with exacerbation of parkinsonism due to dural arteriovenous fistula
Keito Ishihara, Hiroyuki Naito, Takeshi Hara, Tomohisa Nezu, Shiro Aoki, Daizo Ishii, Nobutaka Horie, Hirofumi Maruyama
Japanese Journal of Stroke.2024;[Epub] CrossRef
Secondary parkinsonism associated with focal brain lesions
Rok Berlot, Anđela Pavlović, Maja Kojović
Frontiers in Neurology.2024;[Epub] CrossRef
The Sudden Onset of Pure Parkinsonism Caused by Intracranial Dural Arteriovenous Fistulas
Hitoshi Kawasaki, Risa Okuda, Ryu Yokoyama, Toshimasa Yamamoto
Internal Medicine.2022; 61(7): 1059. CrossRef
Reversible Parkinsonism and Rapidly Progressive Dementia Due to Dural Arteriovenous Fistula: Case Series and Literature Review
Joshua Lai, Manraj K.S. Heran, A. Jon Stoessl, Peter A. Gooderham
Movement Disorders Clinical Practice.2017; 4(4): 607. CrossRef
Dementia and Parkinsonism-a Rare Presentation of Intracranial Dural Arteriovenous Fistulae
Manoj Gopinath, Chinmay Nagesh, K Santhosh, ER Jayadevan
Neurointervention.2017; 12(2): 125. CrossRef
Straight sinus dural arteriovenous fistula presenting with reversible parkinsonism
Jiali Pu, Xiaoli Si, Rong Ye, Baorong Zhang
Medicine.2017; 96(49): e9005. CrossRef

Nonmotor Symptoms and Subthalamic Deep Brain Stimulation in Parkinson’s Disease: Han-Joon Kim, Beom S. Jeon, Sun Ha Paek; J Mov Disord. 2015;8(2):83-91. Published online May 31, 2015; DOI: https://doi.org/10.14802/jmd.15010

25,341 View
250 Download
57 Web of Science
51 Crossref

Abstract PDF

Subthalamic deep brain stimulation (STN DBS) is an established treatment for the motor symptoms in patients with advanced Parkinson’s disease (PD). In addition to improvements in motor symptoms, many studies have reported changes in various nonmotor symptoms (NMSs) after STN DBS in patients with PD. Psychiatric symptoms, including depression, apathy, anxiety, and impulsivity, can worsen or improve depending on the electrical stimulation parameters, the locations of the stimulating contacts within the STN, and changes in medications after surgery. Global cognitive function is not affected by STN DBS, and there is no increase in the incidence of dementia after STN DBS compared to that after medical treatment, although clinically insignificant declines in verbal fluency have been consistently reported. Pain, especially PD-related pain, improves with STN DBS. Evidence regarding the effects of STN DBS on autonomic symptoms and sleep-related problems is limited and remains conflicting. Many symptoms of nonmotor fluctuations, which are occasionally more troublesome than motor fluctuations, improve with STN DBS. Although it is clear that NMSs are not target symptoms for STN DBS, NMSs have a strong influence on the quality of life of patients with PD, and clinicians should thus be aware of these NMSs when deciding whether to perform surgery and should pay attention to changes in these symptoms after STN DBS to ensure the optimal care for patients.

Citations

Citations to this article as recorded by

Preoperative Attention/Memory Problem Affects the Quality of Life of Parkinson’s Disease Patients after Deep Brain Stimulation: A Cohort Study
Ying Gao, Jue Wang, Linbin Wang, Dianyou Li, Bomin Sun, Xian Qiu, Shiek Ahmed
Parkinson's Disease.2024; 2024: 1. CrossRef
Neurocognitive changes at different follow-up times after bilateral subthalamic nucleus deep brain stimulation in patients with Parkinson's disease
Zhuohang Wang, Zijian Zheng, Junwen Huang, Xu Cai, Xinjie Liu, Cheng Xue, Longping Yao, Guohui Lu
Heliyon.2024; 10(4): e26303. CrossRef
Investigation of the nonmotor symptoms in patients with STN-DBS therapy in comparison with those without STN-DBS
Halil Onder, Selcuk Comoglu
Journal of Neural Transmission.2024; 131(8): 931. CrossRef
The Protective Role of Cognitive Reserve: A Preliminary Study on Parkinsonian Patients Undergoing Deep Brain Stimulation
Eleonora Zirone, Fabiana Ruggiero, Maria Takeko Molisso, Roberta Ferrucci, Angelica De Sandi, Angelica Marfoli, Denise Mellace, Filippo Cogiamanian, Linda Borellini, Enrico Mailland, Elena Pirola, Antonella Ampollini, Marco Locatelli, Sergio Barbieri, Fra
Journal of Clinical Medicine.2024; 13(15): 4578. CrossRef
Circuit-Specific Deep Brain Stimulation Provides Insights into Movement Control
Aryn H. Gittis, Roy V. Sillitoe
Annual Review of Neuroscience .2024; 47(1): 63. CrossRef
An escape-enhancing circuit involving subthalamic CRH neurons mediates stress-induced anhedonia in mice
Binghao Zhao, Lisha Liang, Jingfei Li, Bernhard Schaefke, Liping Wang, Yu-Ting Tseng
Neurobiology of Disease.2024; 200: 106649. CrossRef
Effect of deep brain stimulation on sexual dysfunction among patients who had Parkinson’s disease: a systematic review and meta-analysis
Amir Reza Bahadori, Rasa Zafari, Mohammad Amin Fathollahi, Afshan Davari, Mehrdad Sheikhvatan, Sara Ranji, Abbas Tafakhori
Neurological Research.2024; : 1. CrossRef
A Wellness Prescription for Parkinson's: Mid to Late-stage Disease
Gregory M Pontone, Bradley McDaniels, Adrienne M Keener, Indu Subramanian
The American Journal of Geriatric Psychiatry.2023;[Epub] CrossRef
Impact of deep brain stimulation (DBS) on olfaction in Parkinson's disease: Clinical features and functional hypotheses
G. Brand, C. Bontempi, L. Jacquot
Revue Neurologique.2023; 179(9): 947. CrossRef
Time-locked acute alpha-frequency stimulation of subthalamic nuclei during the evaluation of emotional stimuli and its effect on power modulation
Naeem Muhammad, Saurabh Sonkusare, Qiong Ding, Linbin Wang, Alekhya Mandali, Yi Jie Zhao, Bomin Sun, Dianyou Li, Valerie Voon
Frontiers in Human Neuroscience.2023;[Epub] CrossRef
Nutraceuticals a Food for Thought in the Treatment of Parkinson’s Disease
Keshav Bansal, Sakshi Singh, Vanshita Singh, Meenakshi Bajpai
Current Nutrition & Food Science.2023; 19(9): 961. CrossRef
Subthalamic Nucleus Stimulation in Parkinson's Disease: 5‐Year Extension Study of a Randomized Trial
Silje Bjerknes, Mathias Toft, Reidun Brandt, Trine Waage Rygvold, Ane Konglund, Espen Dietrichs, Stein Andersson, Inger Marie Skogseid
Movement Disorders Clinical Practice.2022; 9(1): 48. CrossRef
Effects of subthalamic deep brain stimulation on non‐motor symptoms of Parkinson's disease: A meta‐analysis
Zahra Eghlidos, Zahra Rahimian, Gholamreza Vadiee, Soodeh Jahangiri
Acta Neurologica Scandinavica.2022; 146(2): 115. CrossRef
Nomogram for Predicting Depression Improvement after Deep Brain Stimulation for Parkinson’s Disease
Bowen Chang, Chen Ni, Jiaming Mei, Chi Xiong, Peng Chen, Manli Jiang, Chaoshi Niu
Brain Sciences.2022; 12(7): 841. CrossRef
A nigra–subthalamic circuit is involved in acute and chronic pain states
Cui Yin, Tao Jia, Yiwen Luan, Xue Zhang, Cheng Xiao, Chunyi Zhou
Pain.2022; 163(10): 1952. CrossRef
A nigro–subthalamo–parabrachial pathway modulates pain-like behaviors
Tao Jia, Ying-Di Wang, Jing Chen, Xue Zhang, Jun-Li Cao, Cheng Xiao, Chunyi Zhou
Nature Communications.2022;[Epub] CrossRef
Basal impulses: findings from the last twenty years on impulsivity and reward pathways using deep brain stimulation
Pavan S. UPADHYAYULA, Robert C. RENNERT, Joel R. MARTIN, John K. YUE, Jason YANG, Eva M. GILLIS-BUCK, Nikki SIDHU, Christopher K. CHEUNG, Anthony T. LEE, Reid R. HOSHIDE, Joseph D. CIACCI
Journal of Neurosurgical Sciences.2021;[Epub] CrossRef
Pallidal versus subthalamic deep-brain stimulation for meige syndrome: a retrospective study
Jiayu Liu, Hu Ding, Ke Xu, Ruen Liu, Dongliang Wang, Jia Ouyang, Zhi Liu, Zeyu Miao
Scientific Reports.2021;[Epub] CrossRef
Eight‐year follow‐up outcome of subthalamic deep brain stimulation for Parkinson’s disease: Maintenance of therapeutic efficacy with a relatively low levodopa dosage and stimulation intensity
Lulu Jiang, Wanru Chen, Qiyu Guo, Chao Yang, Jing Gu, Wenbiao Xian, Yanmei Liu, Yifan Zheng, Jing Ye, Shaohua Xu, Yu Hu, Lei Wu, Jie Chen, Hao Qian, Xiaoli Fu, Jinlong Liu, Ling Chen
CNS Neuroscience & Therapeutics.2021; 27(11): 1366. CrossRef
Clinical Impact of Deep Brain Stimulation on the Autonomic System in Patients with Parkinson's Disease
Gabriele Bellini, Laura A. Best, Una Brechany, Russell Mills, Nicola Pavese
Movement Disorders Clinical Practice.2020; 7(4): 373. CrossRef
Reversal of hyperactive subthalamic circuits differentially mitigates pain hypersensitivity phenotypes in parkinsonian mice
Yiwen Luan, Dongliang Tang, Haichuan Wu, Weixin Gu, Yuqing Wu, Jun-Li Cao, Cheng Xiao, Chunyi Zhou
Proceedings of the National Academy of Sciences.2020; 117(18): 10045. CrossRef
Impulsivity and Compulsivity After Subthalamic Deep Brain Stimulation for Parkinson’s Disease
Sara Scherrer, Andrew H. Smith, Jaimie Gowatsky, Christina A. Palmese, Joohi Jimenez-Shahed, Brian H. Kopell, Helen S. Mayberg, Martijn Figee
Frontiers in Behavioral Neuroscience.2020;[Epub] CrossRef
Deep brain stimulation and recordings: Insights into the contributions of subthalamic nucleus in cognition
Neil M. Drummond, Robert Chen
NeuroImage.2020; 222: 117300. CrossRef
Bilateral Subthalamic Nucleus Deep Brain Stimulation under General Anesthesia: Literature Review and Single Center Experience
Hye Ran Park, Yong Hoon Lim, Eun Jin Song, Jae Meen Lee, Kawngwoo Park, Kwang Hyon Park, Woong-Woo Lee, Han-Joon Kim, Beomseok Jeon, Sun Ha Paek
Journal of Clinical Medicine.2020; 9(9): 3044. CrossRef
Subthalamic deep brain stimulation improves sleep and excessive sweating in Parkinson’s disease
Silje Bjerknes, Inger Marie Skogseid, Tuva Jin Hauge, Espen Dietrichs, Mathias Toft
npj Parkinson's Disease.2020;[Epub] CrossRef
Impacto de la estimulación subtalámica a largo plazo sobre la situación cognitiva de los pacientes con enfermedad de Parkinson avanzada
M. Acera, A. Molano, B. Tijero, G. Bilbao, I. Lambarri, R. Villoria, J. Somme, E. Ruiz de Gopegui, I. Gabilondo, J.C. Gomez-Esteban
Neurología.2019; 34(9): 573. CrossRef
The Subthalamic Nucleus: Unravelling New Roles and Mechanisms in the Control of Action
Tora Bonnevie, Kareem A. Zaghloul
The Neuroscientist.2019; 25(1): 48. CrossRef
Modulation of specific components of sleep disturbances by simultaneous subthalamic and nigral stimulation in Parkinson's disease
U. Hidding, A. Gulberti, C. Pflug, C. Choe, A. Horn, L. Prilop, H. Braaß, O. Fründt, C. Buhmann, D. Weiss, M. Westphal, A.K. Engel, C. Gerloff, J.A. Köppen, W. Hamel, C.K.E. Moll, M. Pötter-Nerger
Parkinsonism & Related Disorders.2019; 62: 141. CrossRef
Zona incerta GABAergic neurons integrate prey-related sensory signals and induce an appetitive drive to promote hunting
Zheng-dong Zhao, Zongming Chen, Xinkuan Xiang, Mengna Hu, Hengchang Xie, Xiaoning Jia, Fang Cai, Yuting Cui, Zijun Chen, Lechen Qian, Jiashu Liu, Congping Shang, Yiqing Yang, Xinyan Ni, Wenzhi Sun, Ji Hu, Peng Cao, Haohong Li, Wei L. Shen
Nature Neuroscience.2019; 22(6): 921. CrossRef
Long-term impact of subthalamic stimulation on cognitive function in patients with advanced Parkinson's disease
M. Acera, A. Molano, B. Tijero, G. Bilbao, I. Lambarri, R. Villoria, J. Somme, E. Ruiz de Gopegui, I. Gabilondo, J.C. Gomez-Esteban
Neurología (English Edition).2019; 34(9): 573. CrossRef
Influencia de la estimulación cerebral profunda en la carga de cuidadores de pacientes con enfermedad de Parkinson
J.A. Crespo-Burillo, D. Rivero-Celada, A. Saenz-de Cabezón, J. Casado-Pellejero, J. Alberdi-Viñas, R. Alarcia-Alejos
Neurología.2018; 33(3): 154. CrossRef
Alteration in the Local and Global Functional Connectivity of Resting State Networks in Parkinson’s Disease
Maryam Ghahremani, Jaejun Yoo, Sun Ju Chung, Kwangsun Yoo, Jong C. Ye, Yong Jeong
Journal of Movement Disorders.2018; 11(1): 13. CrossRef
Deep brain stimulation for patients with Parkinson's disease: Effect on caregiver burden
J.A. Crespo-Burillo, D. Rivero-Celada, A. Saenz-de Cabezón, J. Casado-Pellejero, J. Alberdi-Viñas, R. Alarcia-Alejos
Neurología (English Edition).2018; 33(3): 154. CrossRef
Clinical Markers of Anxiety Subtypes in Parkinson Disease
Martinus P. G. Broen, A. F. G. Leentjens, J. T. Hinkle, A. J. H. Moonen, M. L. Kuijf, N. M. Fischer, K. Perepezko, A. Bakker, G. M. Pontone
Journal of Geriatric Psychiatry and Neurology.2018; 31(2): 55. CrossRef
Apathy following Bilateral Deep Brain Stimulation of Subthalamic Nucleus in Parkinson’s Disease: A Meta-Analysis
Ying Wang, Yongsheng Li, Xiaona Zhang, Anmu Xie
Parkinson's Disease.2018; 2018: 1. CrossRef
Non-motor Characterization of the Basal Ganglia: Evidence From Human and Non-human Primate Electrophysiology
Robert S. Eisinger, Morgan E. Urdaneta, Kelly D. Foote, Michael S. Okun, Aysegul Gunduz
Frontiers in Neuroscience.2018;[Epub] CrossRef
Revealing a novel nociceptive network that links the subthalamic nucleus to pain processing
Arnaud Pautrat, Marta Rolland, Margaux Barthelemy, Christelle Baunez, Valérie Sinniger, Brigitte Piallat, Marc Savasta, Paul G Overton, Olivier David, Veronique Coizet
eLife.2018;[Epub] CrossRef
Cerebrospinal fluid protein markers in PD patients after DBS-STN surgery—A retrospective analysis of patients that underwent surgery between 1993 and 2001
Radu Constantinescu, Kaj Blennow, Lars Rosengren, Barbro Eriksson, Thordis Gudmundsdottir, Yvonne Jansson, Bo Johnels, Annika Renck, Filip Bergquist
Clinical Neurology and Neurosurgery.2018; 174: 174. CrossRef
Predictors to quality of life improvements after subthalamic stimulation in Parkinson’s disease
Feng‐Tao Liu, Li‐Qin Lang, Yu‐Jie Yang, Jue Zhao, Rui Feng, Jie Hu, Jian Wang, Jian‐Jun Wu
Acta Neurologica Scandinavica.2018;[Epub] CrossRef
Apathy associated with neurocognitive disorders: Recent progress and future directions
Krista L. Lanctôt, Luis Agüera‐Ortiz, Henry Brodaty, Paul T. Francis, Yonas E. Geda, Zahinoor Ismail, Gad A. Marshall, Moyra E. Mortby, Chiadi U. Onyike, Prasad R. Padala, Antonios M. Politis, Paul B. Rosenberg, Emma Siegel, David L. Sultzer, Eleenor H. A
Alzheimer's & Dementia.2017; 13(1): 84. CrossRef
Can deep brain stimulation be a therapeutic option for Parkinson's disease dementia?
Han‐Joon Kim, Beomseok Jeon, Jee‐Young Lee, Sun Ha Paek
Neurology and Clinical Neuroscience.2017; 5(1): 3. CrossRef
The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence
Mónica M Kurtis, Thadshani Rajah, Luisa F Delgado, Haidar S Dafsari
npj Parkinson's Disease.2017;[Epub] CrossRef
Delayed responses of subthalamic nucleus to deep brain stimulation in patients with Parkinson's disease
Lin Shi, Kai Zhang, Fan-Gang Meng, Guan-Yu Zhu, Ying-Chuan Chen, Jun-Jian Zhou, Zhong-Hai Zhou, Jian-Guo Zhang
Parkinsonism & Related Disorders.2017; 40: 76. CrossRef
Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease
Margherita Fabbri, Miguel Coelho, Leonor Correia Guedes, Mario M. Rosa, Daisy Abreu, Nilza Gonçalves, Angelo Antonini, Joaquim J. Ferreira
Parkinsonism & Related Disorders.2017;[Epub] CrossRef
Deep Brain Stimulation of Hemiparkinsonian Rats with Unipolar and Bipolar Electrodes for up to 6 Weeks: Behavioral Testing of Freely Moving Animals
Kathrin Badstuebner, Ulrike Gimsa, Immo Weber, Armin Tuchscherer, Jan Gimsa
Parkinson's Disease.2017; 2017: 1. CrossRef
Current Topics in Deep Brain Stimulation for Parkinson Disease
Atsushi UMEMURA, Genko OYAMA, Yasushi SHIMO, Madoka NAKAJIMA, Asuka NAKAJIMA, Takayuki JO, Satoko SEKIMOTO, Masanobu ITO, Takumi MITSUHASHI, Nobutaka HATTORI, Hajime ARAI
Neurologia medico-chirurgica.2016; 56(10): 613. CrossRef
In Parkinson’s disease STN stimulation enhances responsiveness of movement initiation speed to high reward value
Maja Kojovic, Andrea Higgins, Marjan Jahanshahi
Neuropsychologia.2016; 89: 273. CrossRef
Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson’s Disease
Lei-Fang Cao, Xiao-Yan Peng, Ya Huang, Bing Wang, Feng-Ming Zhou, Ruo-Xiao Cheng, Li-Hua Chen, Wei-Feng Luo, Tong Liu
Neural Plasticity.2016; 2016: 1. CrossRef
The KMDS-NATION Study: Korean Movement Disorders Society Multicenter Assessment of Non-Motor Symptoms and Quality of Life in Parkinson's Disease NATION Study Group
Do-Young Kwon, Seong-Beom Koh, Jae Hyeok Lee, Hee Kyung Park, Han-Joon Kim, Hae-Won Shin, Jinyoung Youn, Kun Woo Park, Sun-Ah Choi, Sang Jin Kim, Seong-Min Choi, Ji-Yun Park, Beom S. Jeon, Ji Young Kim, Sun Ju Chung, Chong Sik Lee, Jeong-Ho Park, Tae-Beom
Journal of Clinical Neurology.2016; 12(4): 393. CrossRef
Antiparkinsonian Treatment for Depression in Parkinson's Disease: Are Selective Serotonin Reuptake Inhibitors Recommended?
Philippe De Deurwaerdère, Yuqiang Ding
Translational Neuroscience and Clinics.2016; 2(2): 138. CrossRef
The Subthalamic Nucleus, Limbic Function, and Impulse Control
P. Justin Rossi, Aysegul Gunduz, Michael S. Okun
Neuropsychology Review.2015; 25(4): 398. CrossRef

Stiff-Person Syndrome: Case Series: Yu Jin Jung, Han G. Jeong, Ryul Kim, Han-Joon Kim, Beom S. Jeon; J Mov Disord. 2014;7(1):19-21. Published online April 30, 2014; DOI: https://doi.org/10.14802/jmd.14004

14,473 View
1,378 Download
5 Web of Science
4 Crossref

Abstract PDF

Stiff-person syndrome (SPS) is a rare disorder, characterized by progressive fluctuating muscular rigidity and spasms. Glutamic acid decarboxylase (GAD) antibody is primarily involved in the pathogenesis of SPS and SPS is strongly associated with other autoimmune disease. Here we report three cases of patients with classical SPS finally confirmed by high serum level of GAD antibodies. All of our patients respond favorably to gamma amino butyric acid-enhancing drugs and immunotherapies.

Citations

Citations to this article as recorded by

Stiff Person Syndrome in a patient with atypical carcinoid tumor of the lung secondary to anti-amphiphysin antibodies: A case report and literature review
Khawla Abusamra, Mangayarkarasi Thandampallayam, Douglas Lukins, Padmaja Sudhakar
Neuroimmunology Reports.2022; 2: 100116. CrossRef
Efficacy and safety of therapeutic plasma exchange in stiff person syndrome
Piotr F. Czempik, Justyna Gawryluk, Agnieszka Wiórek, Ewa Krzystanek, Łukasz J. Krzych
Open Medicine.2021; 16(1): 526. CrossRef
The computational neurology of movement under active inference
Thomas Parr, Jakub Limanowski, Vishal Rawji, Karl Friston
Brain.2021; 144(6): 1799. CrossRef
Neuronal Antibodies and Associated Syndromes
Borros M. Arneth
Autoimmune Diseases.2019; 2019: 1. CrossRef

Amantadine Induced Corneal Edema in a Patient with Primary Progressive Freezing of Gait: Young Eun Kim, Ji Young Yun, Hui-Jun Yang, Han-Joon Kim, Mee Kum Kim, Won Ryang Wee, Beom S. Jeon; J Mov Disord. 2013;6(2):34-36. Published online October 30, 2013; DOI: https://doi.org/10.14802/jmd.13008

19,051 View
79 Download
8 Crossref

Abstract PDF

Amantadine is commonly used for Parkinsonism. However amantadine can induce adverse corneal reaction. Here we report a patient with primary progressive freezing of gait who had severe corneal edema associated with amantadine, which was reversible after discontinuation of the amantadine. This report alerts neurologists for this reversible but potentially critical corneal edema in patients with Parkinsonism who are receiving amantadine.

Citations

Citations to this article as recorded by

Amantadine-induced corneal edema – A reversible cause of visual blurring in Parkinson’s disease
Jacky Ganguly, Soumava Mukherjee, Nilam Singh, Hrishikesh Kumar
Annals of Movement Disorders.2024;[Epub] CrossRef
Amantadine-induced corneal edema: A case and literature review
Antony Raharja, Wessam Mina, Zahra Ashena
American Journal of Ophthalmology Case Reports.2023; 32: 101881. CrossRef
Experience of diagnosis and managements for patients with primary progressive freezing of gait
Li-Li Zhang, Ya-Jie Zhao, Liang Zhang, Xiao-Ping Wang
Journal of Neurorestoratology.2022; : 100039. CrossRef
Toxicity of amantadine hydrochloride on cultured bovine cornea endothelial cells
Po-Yen Lee, Yu-Hung Lai, Po-Len Liu, Ching-Chih Liu, Chia-Cheng Su, Fang-Yen Chiu, Wei-Chung Cheng, Shiuh-Liang Hsu, Kai-Chun Cheng, Li-Yi Chiu, Tzu-En Kao, Chia-Ching Lin, Yo-Chen Chang, Shu-Chi Wang, Chia-Yang Li
Scientific Reports.2021;[Epub] CrossRef
Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia
Santiago Perez-Lloret, Olivier Rascol
Journal of Neural Transmission.2018; 125(8): 1237. CrossRef
Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked
Merel S. Ekker, Sabine Janssen, Klaus Seppi, Werner Poewe, Nienke M. de Vries, Thomas Theelen, Jorik Nonnekes, Bastiaan R. Bloem
Parkinsonism & Related Disorders.2017; 40: 1. CrossRef
Parkinson’s disease between internal medicine and neurology
Ilona Csoti, Wolfgang H. Jost, Heinz Reichmann
Journal of Neural Transmission.2016; 123(1): 3. CrossRef
Amantadine Use as a Risk Factor for Corneal Edema: A Nationwide Cohort Study in Taiwan
Po Yen Lee, Hung Pin Tu, Chang Ping Lin, Cheng Hsien Chang, Kai Chun Cheng, Chia Ching Lin, Shiuh Liang Hsu
American Journal of Ophthalmology.2016; 171: 122. CrossRef

A Case of Adrenoleukodystrophy Presenting as Progressive Cerebellar Dysfunction: Seunguk Jung, Jong Won Chung, Ji Young Yun, Han-Joon Kim, Beom Seok Jeon; J Mov Disord. 2009;2(2):91-94.; DOI: https://doi.org/10.14802/jmd.09025

14,972 View
91 Download
4 Crossref

Abstract PDF

X-linked adrenoleukodystrophy (X-ALD) is a hereditary neurological disorder affecting the nervous system and adrenal cortex. The phenotype of X-ALD ranges from the rapidly progressive cerebral form to milder adrenomyeloneuropathy. However, cerebellar manifestations are rare. We report a case of adrenoleukodystrophy presenting as progressive cerebellar dysfunction resembling olivopontocerebellar degeneration, with a review of the literature

Citations

Citations to this article as recorded by

Gut dysmotility in children with neurological impairment: the nutritional management
Antonio Corsello, Lorenzo Scatigno, Annalisa Govoni, Gianvincenzo Zuccotti, Frédéric Gottrand, Claudio Romano, Elvira Verduci
Frontiers in Neurology.2023;[Epub] CrossRef
Leukoencephalopathy With Predominant Infratentorial Involvement Caused by a Novel ABCD1 Mutation
Chiara Benzoni, Laura Farina, Viviana Pensato, Giorgio Marotta, Altin Kuqo, Elena Mauro, Davide Pareyson, Ettore Salsano
The Neurologist.2019; 24(6): 194. CrossRef
Unmasking adrenoleukodystrophy in a cohort of cerebellar ataxia
Ying-Hao Chen, Yi-Chung Lee, Yu-Shuen Tsai, Yuh-Cherng Guo, Cheng-Tsung Hsiao, Pei-Chien Tsai, Jin-An Huang, Yi-Chu Liao, Bing-Wen Soong, Zhi-Ying Wu
PLOS ONE.2017; 12(5): e0177296. CrossRef
Adult‐onset cerebello‐brainstem dominant form of X‐linked adrenoleukodystrophy presenting as multiple system atrophy: case report and literature review
Kotaro Ogaki, Shunsuke Koga, Naoya Aoki, Wenlang Lin, Kinuko Suzuki, Owen A. Ross, Dennis W. Dickson
Neuropathology.2016; 36(1): 64. CrossRef

Author index